CLINICAL PROTOCOL  
Document Date: Version 2.0, 07 Dec 2021 
NCT #: [STUDY_ID_REMOVED] 
 
 
Lumen Bioscience, Inc.  Confidential  Page 1 Clinical Protocol  
 
A Phase 2 Randomized, Double -Blind, Placebo -Controlled, 
Single Dose  Regimen Study of  LMN -101 in Healthy Volunteers 
Challenged with Campylobacter jejuni  
 
Study Number CAM02  
 
 
 
Investigational Product: LMN -101  
 
VHH -derived binding protein designed to bind and inhibit FlaA, flagellin protein of  
Campylobacter jejuni , delivered in whole spray -dried, spirulina biomass  
 
 
 
Version 2.0   
 
December  7, 2021  
 
 
 
 
 
Statement of Confidentiality  
Information contained within the Clinical Protocol, including unpublished data, is the property of Lumen 
Bioscience, Inc. and is provided in strict confidence to Investigators, potential Investigators, or 
consultants for review. This information shall not be disclosed to third parties without prior written 
authorization from Lumen Bioscience, Inc. except as necessary to obtain informed consent from study 
participants who may receive this p roduct.  Principal Investigator : 
Mohamed Al -Ibrahim, MB, ChB, 
FACP  
Pharmaron  Clinical Research 
Center  
800 West Baltimore Street  
Baltimore, MD, 21201 , USA  Company Sponsor : 
Lumen Bioscience, Inc.  
1441 N. 34th Street, Suite 300  
Seattle, WA 98103, USA  
(206) 899 -1904  
www.lumen.bio  
Lumen Bioscience, Inc.  Confidential  Page 2 INVESTIGATOR’S AGREEMENT  
 
A Phase 2 Randomized, Double -Blind, Placebo -Controlled, Single Dose  Regimen Study of  
LMN -101 in Healthy Volunteers Challenged with Campylobacter jejuni  
I have received and read the Investigators’ Brochure for LMN -101. I h ave read th is clinical 
protocol and agree to conduct the study as outlined in this protocol and according to the 
International Conference on Harmonisation (ICH) guidelines, The Nuremberg Code, The Belmont 
Report, The Declaration of Helsinki 2000, US 21 CFR Part 50 --Protection of Human Subjects, 32 
CFR 219 (The Common Rule), and all regulations pertinent to the Department of Defense , and 
relevant regional  and/or national  laws. Confidentiality of all information received or developed 
in connection with thi s protocol will be maintained by me, as well as all other personnel involved 
in the clinical trial who are employed  or contracted  by me  or my organization . 
 
   
 
 
_______________________________ ________                            _____________________________  
  
Mohamed Al -Ibrahim, MB, ChB, FACP                    Date  
Site Principal Investigator  
 
 
SPONSOR SIGNATURE  
  
 
   ___________________________                 ______________________  
    
Carl Mason, MD                                                             Date  
Senior Medical Director  
  
Lumen Bioscience, Inc.  Confidential  Page 3  
Protocol amendments April 28 , 202 1, Version 2.0   
General rewrite for clarity and linearity improvements  All 
Added Inclusion criteria for screening labs defined as ≤ Grade 1 on CTCAE v. 5.0  Section 7.2 
Exclusion for immunomodulating agents, including chemotherapy, extended to 
12 months  Section 7.3 
Addition of the following conditions to the exclusion criteria:  inflammatory 
bowel disease; autoimmune disease; malignancy; any immunocompromising 
condition; or history of major gastrointestinal surgery  Section 7.3 
Noted that IntegReview is the IRB for review of study documents, amendments, 
and SAEs. The NMR C IRB has delegated IRB review responsibilities to 
IntegReview IRB  Sections 7.1, 
11.11 , and 11.11.2  
Duration of collection of types of adverse events clarified  Schedule of 
Evaluations, 
Section  11.9  
Added management plan for subjects who develop Campyloba cter bacteremia  Section 8.11 
Clarified that all adverse events will be reported regardless of causality  Section 11.2 
Definition of causality added  Section 11.4  
Included Sponsor requirements for reporting to FDA  Section 11.11.3  
Exclusion of grade 3 Campylobacter symptoms from the halting criteria is limited 
to the in  clinical research center  period  Section 11.14  
Statistical Plan updated  Section 12 
Duplicate References Removed  Section 14  
  
Lumen Bioscience, Inc.  Confidential  Page 4 1. Table of Contents  
1. Table of Contents  ................................ ................................ ................................ ....................... 4 
2. Synopsis  ................................ ................................ ................................ ................................ .....9 
3. Schedule  ................................ ................................ ................................ ................................ .. 14 
4. Introduction  ................................ ................................ ................................ .............................  18 
4.1 Background and  study rationale  ................................ ................................ ................................ . 18 
4.2 Dosage rationale  ................................ ................................ ................................ .........................  19 
4.3 Controlled human infection C. jejuni challenge model  ................................ ...............................  19 
5. Objectives and Endpoints  ................................ ................................ ................................ ..........  20 
5.1 Study Objectives  ................................ ................................ ................................ ..........................  20 
5.2 Study Endpoints  ................................ ................................ ................................ ...........................  21 
6. Study Design  ................................ ................................ ................................ ............................  22 
6.1 General Schema of Study Design  ................................ ................................ ................................  22 
6.2 Study Duration, Enrollment, and Number of Sites  ................................ ................................ ...... 22 
6.3 Risks/benefits  ................................ ................................ ................................ ..............................  23 
7. Study Population  ................................ ................................ ................................ ......................  25 
7.1 Recruitment, screening, and enrollment of study volunteers  ................................ .....................  25 
7.2 Inclusion Criteria  ................................ ................................ ................................ .........................  25 
7.3 Exclusion Criteria  ................................ ................................ ................................ .........................  26 
8. Study Schedule  ................................ ................................ ................................ .........................  27 
8.1 Screening (Two months prior to stu dy start)  ................................ ................................ ..............  27 
8.2 Study -Specific Screening (Three weeks prior to start)  ................................ ................................ . 28 
8.3 Treatment Phase  ................................ ................................ ................................ .........................  28 
8.4 Follow -up Phase  ................................ ................................ ................................ ..........................  31 
8.5 Recrudescent infection and recrudescent follow -up plan  ................................ ...........................  32 
8.6 Assessment of subject compliance with investigational products  ................................ ..............  33 
8.7 Concomitant medications  ................................ ................................ ................................ ...........  33 
8.8 Early termination  ................................ ................................ ................................ ........................  33 
8.9 Randomization  ................................ ................................ ................................ ............................  34 
8.10  Blinding  ................................ ................................ ................................ ................................ .......  34 
8.11  Fluid and bacteremia management  ................................ ................................ ............................  34 
8.11.1  Oral fluid replacement  ................................ ................................ ..............................  34 
8.11.2  Criteria for IV fluid replacement  ................................ ................................ ...............  34 
8.11.3  Criteria for serum electrolyte monitoring  ................................ ................................ . 34 
8.11.4  Criteria for blood culture surveillance  ................................ ................................ .......  34 
8.11.5  Management plan for Campylobacter jejuni bacteremia.  ................................ ...... 34 
8.12  Planned antibiotic treatment phase  ................................ ................................ ...........................  35 
8.12.1  Criteria for early treatment with antibiotics  ................................ .............................  35 
9. Study Evaluations  ................................ ................................ ................................ .....................  35 
Lumen Bioscience, Inc.  Confidential  Page 5 9.1 Specimen preparation, handling, and shipping  ................................ ................................ ..........  35 
9.2 Clinical laboratory evaluations ................................ ................................ ................................ .... 36 
9.3 Clinical evaluations  ................................ ................................ ................................ .....................  36 
9.4 Phar macokinetics  ................................ ................................ ................................ ........................  38 
10. Investigational product  ................................ ................................ ................................ .............  38 
10.1  Investigational product  ................................ ................................ ................................ ...............  38 
10.2  Dosing regimen of investigational product  ................................ ................................ .................  39 
10.3  Dispensing of investigational product  ................................ ................................ .........................  39 
10.4  Dosage form of investigational product  ................................ ................................ .....................  39 
10.5  Route of administration of investigational product  ................................ ................................ .... 39 
10.6  Timing of dosing of investigational product  ................................ ................................ ...............  40 
10.7  Packaging and labeling of investigational pro duct  ................................ ................................ ..... 40 
10.8  Storage and handling of investigational product  ................................ ................................ .......  40 
10.9  C. jejuni challenge strain CG8421 ................................ ................................ ................................  40 
10.10  Preparation of challenge str ain ................................ ................................ ................................ ... 41 
10.11  Packaging and labeling of challenge strain  ................................ ................................ ................  41 
10.12  Storage and transportation of challenge strain  ................................ ................................ ..........  41 
10.13  Preparation, administration, and inoculum size of chal lenge strain  ................................ ..........  42 
10.14  Antibiotics  ................................ ................................ ................................ ................................ ... 42 
10.15  Assessment of subject compliance with investigational products  ................................ ..............  42 
10.16  Missed doses of LMN -101 or placebo  ................................ ................................ .........................  42 
11. Safety Management  ................................ ................................ ................................ .................  43 
11.1  Adverse events  ................................ ................................ ................................ ............................  43 
11.2  Definitions  ................................ ................................ ................................ ................................ ... 43 
11.3  Assessment of severity  ................................ ................................ ................................ ................  44 
11.4  Assessment of causality  ................................ ................................ ................................ ..............  45 
11.5  Anticipated adverse events  ................................ ................................ ................................ .........  46 
11.6 Out of unit adverse events  ................................ ................................ ................................ ..........  47 
11.7  In unit participant surveillance  ................................ ................................ ................................ .... 47 
11.8  Out of unit surveillance  ................................ ................................ ................................ ...............  48 
11.8.1  Discharge to Day 59  ................................ ................................ ................................ .. 48 
11.8.2  Day 59 to Day 190 ................................ ................................ ................................ ..... 48 
11.9  Recording adverse events  ................................ ................................ ................................ ...........  48 
11.10  Follow -up of adverse events and assessment of outcome  ................................ ..........................  48 
11.11  Reporting serious adverse events  ................................ ................................ ...............................  49 
11.11.1  Sponsor notification by Principal Investigator  ................................ ..........................  49 
11.11.2  Institutional Review Boards  ................................ ................................ ......................  50 
11.11.3  FDA notification by Sponsor  ................................ ................................ ......................  50 
11.12  Follow -up of serious adverse events  ................................ ................................ ...........................  51 
11.13  Treatment of adverse events  ................................ ................................ ................................ ...... 51 
11.14  Discontinuation/withdrawal from study  ................................ ................................ .....................  51 
11.15  Right to terminate the study  ................................ ................................ ................................ .......  52 
Lumen Bioscience, Inc.  Confidential  Page 6 12. Statistical considerations  ................................ ................................ ................................ ..........  52 
12.1  Statistical hypothesis  ................................ ................................ ................................ ..................  52 
12.2  Sample size considerations  ................................ ................................ ................................ .........  52 
12.3  Population  ................................ ................................ ................................ ................................ ... 53 
12.4  Statistical Analyses  ................................ ................................ ................................ ......................  53 
12.4.1  General Considerations  ................................ ................................ .............................  53 
12.4.2  Safety Analysis  ................................ ................................ ................................ ..........  53 
12.4.3  Analysis of Efficacy  ................................ ................................ ................................ .... 54 
12.4.4  Planned Interim Analysis  ................................ ................................ ..........................  55 
13. Data handling an d recordkeeping  ................................ ................................ ..............................  55 
14. Clinical trial material accountability  ................................ ................................ ..........................  56 
15. Quality control (QC)/quality assurance (QA)  ................................ ................................ ..............  56 
15.1  QC/QA monitoring  ................................ ................................ ................................ ......................  56 
15.2  Audits and inspections  ................................ ................................ ................................ ................  57 
15.3  Protocol deviation management  ................................ ................................ ................................  57 
15.4  Clinical research monitoring  ................................ ................................ ................................ .......  57 
15.5  Medical Monitor (Sponsor)/Independent Medical Monitor  ................................ ........................  58 
16. Regulatory, ethical and study oversight considerations  ................................ ..............................  58 
16.1  Institutional Review Board  ................................ ................................ ................................ ..........  58 
16.2  Written informed consent  ................................ ................................ ................................ ...........  59 
16.3  Subject risk -mitigation strategies  ................................ ................................ ...............................  59 
16.4  Benefits  ................................ ................................ ................................ ................................ .......  61 
16.5  Subject compensation  ................................ ................................ ................................ .................  61 
16.6  Provisions to protect privacy of subjects and confidentiality of data  ................................ .........  61 
16.7  Safeguards for vulnerable subjects  ................................ ................................ .............................  61 
17. References  ................................ ................................ ................................ ...............................  62 
  
Lumen Bioscience, Inc.  Confidential  Page 7 Abbreviations and Specialist Terms  
Abbreviation  Definition  
AE Adverse event  
AESI  Adverse events of special interest  
CBC Complete blood count  
CFU Colony -forming unit 
CLIA  Clinical Laboratory Improvement Act  
CRA Clinical Research Associate  
 CRF  Case report form  
CRP C-reactive protein  
  CTCAE    Common Terminology Criteria for Adverse Events  
CVD  Center for Vaccine Development  
DoD  Department of Defense  
eCRF  Electronic case report form  
  ECG   Electrocardiogram  
ELISA  Enzyme - linked immunosorbent assay  
ETEC  Enterotoxigenic Escherichia coli  
FQ Fluoroquinolone  
GBS Guillain -Barré syndrome  
GCP Good Clinical Practice  
GE Glycine extract  
GMP  Good Manufacturing Practice  
HBsAg  Hepatitis B surface antigen  
HCV  Hepatitis C virus  
HED  Human -equivalent dose  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human immunodeficiency virus  
IBD Inflammatory bowel disease  
ICF Informed consent form  
IgA Immunoglobulin A  
IgG Immunoglobulin G  
IP Investigational product  
  IND   Investigational new drug  
IRB Institutional Review Board  
IVF Intravenous fluids  
  MCB    Master cell bank  
MIC Minimum inhibition concentration  
Lumen Bioscience, Inc.  Confidential  Page 8 Abbreviation  Definition  
NF National Formulary  
NMRC  Naval Medical Research Center  
NOAEL  No-observed -adverse -event level  
ORS Oral rehydration solution  
PAD  Pharmacologically active dose  
PBMC  Peripheral blood mononuclear  cells 
PE Protective efficacy  
PI Principal Investigator  
SAE Serious adverse event  
  SD   Standard deviation  
  SSP   Site-specific procedure  
ULN  Upper limit of normal  
UMd  University of Maryland  
USP United States Pharmacopoeia  
WBC  White blood cell  
WRAIR  Walter Reed Army Institute of Research  
 
  
Lumen Bioscience, Inc.  Confidential  Page 9  
2. Synopsis  
CLINICAL TRIAL SYNOPSIS  
Study Title:  A Phase 2 Randomized, Double -Blind, Placebo -Controlled, Single Dose  Regimen  
Study of LMN -101 in Healthy Volunteers Challenged with Campylobacter jejuni  
Investigational 
Product:   LMN -101 (VHH -derived binding protein designed to bind and inhibit FlaA, flagellin 
filament protein of Campylobacter jejuni, delivered in whole , spray -dried spirulina 
biomas s) 
Sponsor:  Lumen Bioscience, Inc.  
Research  Center:  Pharmaron  Clinical Research Center , Baltimore, Maryland  
Site PI:  Mohamed Al -Ibrahim, MB, ChB, FACP  
Study 
Objectives : Primary : 
To evaluate the frequency of solicited and unsolicited adverse events in subjects 
that received LMN -101 compared to placebo  
Secondary : 
• To evaluate efficacy based on the proportion of subjects with 
campylobacteriosis in LMN -101 versus placebo recipients after challenge with 
Campylobacter jejuni  
• To evaluate efficacy based on the proportion of subjects with specific solicited 
adverse events in LMN -101 versus  placebo recipients after challenge with 
Campylobacter jejuni  
Exploratory :  
To evaluate in LMN -101 versus placebo recipient s after challenge with 
Campylobacter jejuni : 
• Duration of campylobacteriosis  
• Duration of specific solicited adverse events  
• Severity of campylobacteriosis  
• Severity of specific solicited adverse events  
• Frequency of recurrence of Campylobacter  jejuni  stool shedding  
• Frequency of recurrence of campylobacteriosis clinical symptoms  
• Correlation of the following with severity of illness: serum C -reactive protein, 
fecal total protein, fecal calprotectin, fecal lipocalin, fecal myeloperoxidase, 
fecal neopterin, fecal lactoferrin, fecal cytokines, and/or fecal microbiome  
• Evaluat ion of  systemic absorption of the VHH in LMN -101, and , if VHH is 
detected in serum, pharmacokinetics of the VHH in LMN -101 and formation 
of serum anti -drug antibodies to the VHH in LMN -101 
Lumen Bioscience, Inc.  Confidential  Page 10 Study Design : Randomized, double -blind, placebo -controlled , single dose  regimen  study of 
LMN -101 followed by Campylobacter  jejuni  challenge.   
Subjects  will initially, after documentation  of informed consent,  begin taking their 
assigned LMN -101 or placebo regimen three times daily . After two days , subjects 
will receive the C. jejuni challenge inoculum. Subjects will begin  an appropriate 
antibiotic course upon  meet ing early treatment criteria o r 144 hours  following C. 
jejuni challenge , whichever is earlier.  
Subjects will be  allowed to leave  the clinical research facility 3 days after 
antibiotics, when all symptoms have res olved or are resolving, and have had ≥ 2 
consecutive stool cultures ≥ 12 hours apart negative for C. jejuni  and are afebrile  
> 24 hours prior  to release  and off antipyretics  within 24 hours of discharge . 
Subjects will continue taking their LMN -101 or place bo regimen three times daily  
for a total of 14 days . Subjects will be provided a diary card/memory aid and 
thermometer for at -home monitoring of solicited adverse events through Day 24. 
Subjects will be seen at research facility for protocol -specified evaluations and 
will also be contacted by telephone 6 mon ths after challenge.  
Subject  (N): 42 total subjects will be dosed (21 active, 21 placebo) . A maximum of 200 
subjects will be screened to obtain  approximately 60 eligible subjects . 
Dose Regimen  LMN -101 - six (6) 500-mg capsules orally three times daily for 14 days, or placebo .  
Clinical 
Monitoring  All participants  will be monitored during their in -center portion of the  study . Any 
participant requiring fluid management or other intervention will receive it as 
clinically appropriate.  Participants will be mo nitored for adverse events and 
recrudescence after discharge from  study center  on a daily basis through Day 12 
and at subsequent follow -up visits .  
Discharge from 
Clinical Research  
Unit  Subjects may be released from the clinical research unit  approximately 9-10 days 
following infectious  challenge .  
Release criteria:  
• Treated with antibiotics for at least 3 days  
• Clinical symptoms are resolved or resolving  
• Two stool cultures ≥ 12 hours apart are negative  for C. jejuni  
• Afebrile >24 hours prior to release  and off antipyretics within 24 hours  of discharge.  
PK and PD 
Assessments  Serum samples will be obtained and analyzed  to determine  if any systemic 
absorption is observed , as appr opriate   
Power 
Calculation  With 2 1 subjects receiving LMN -101, there is a 66% probability that an adverse 
event expected to occur in 5% of the population would occur in the study. An 
event with a 10% rate in the population is 89% likely to occur among the 21 LMN -
101 subjects in the study.   
Lumen Bioscience, Inc.  Confidential  Page 11 While the sample size was not selected t o provide a specific amount of statistical 
power to detect a statistically significant difference between the two treatment 
groups, assuming 18 subjects per treatment group complete the study, there is 
80% power to detect a large risk reduction in attack r ates (e.g., from 80% in the 
placebo group to 4 0.6% in the LMN -101 group) at the one -sided significance level 
of 0.05.   
Statistical  
Methods  Frequencies and percentages of subjects with treatment emergent AEs and SAEs 
will be summarized by treatment group, MedDRA preferred term  and system 
organ system class, severity, and relationship to study drug.  
The percentage of subjects with campylobacteriosis or specific solicited adverse 
events will be calculated for each treatment group using the standard definition 
of: (# with endpoint / # receiving inoculum) x 100%.  The risk ratio (LMN -101 / 
placebo) will be presented.  The risk ratio will be tested using the method of 
Cochrane -Mantel -Haenszel stratified by enrollment cohort to determine if the 
risk rati o is statistically significantly different from 1.  
 
Lumen Bioscience, Inc.  Confidential  Page 12 CONTACTS IN CASE OF EMERGENCY  
 
Role in Study  Name  Contact Information  
Site Principal 
Investigator  Mohamed Al -Ibrahim, MB, 
ChB, FACP  
Senior Investigator  
 Pharmaron CPC, Inc.  
800 West Baltimore Street  
6th Floor  
Baltimore, MD 21201  
(410) 706 -8801  
(410) 245 -6888 mobile  
Mohamed.al -ibrahim@pharmaron -us.com  
www.pharmaron.com  
Serious Adverse Event 
Safety Reporting  
 Lea McCauley  
Project Manager  
 Pharmaron CPC, Inc.  
800 West Baltimore Street  
6th Floor  
Baltimore, MD 21201  
(410) 706 -8818 office  
(443) 742 -1316 mobile  
(410) 706 -8964 fax  
lea.mccauley@pharmaron -us.com  
www.pharmaron.com  
Medical Monitor/  
24-Hour  
Emergency Contact  Carl Mason, MD  Lumen Bioscience, Inc.  
1441 N. 34th Street, Suite 300  
Seattle, WA 98103 USA  
(206) 899 -1904 business  
(805)  455-8593  mobile  
cmason@lumen.bio  
Independent Medical 
Monitor/Back -up  
24-Hour  
Emergency Contact  Robert G. Knodell, MD  100 Harborview Drive, #809  
Baltimore Maryland  
(443) 847 -0105 mobile  
knodell809@comcast.net  
 
  
Lumen Bioscience, Inc.  Confidential  Page 13 STUDY COLLABORATORS  
Role in Study  Name  Contact Information  
NMRC Collaborating 
Investigator  Chad Porter, PhD, MPH  
 
 Enteric Diseases Department  
Naval Medical Research Center (NMRC)  
(301) 319 -7505  
(301) 319 -7679 fax  
Chad.k.porter2.civ@mail.mil  
 
CVD Collaborating 
Investigator  Wilbur Chen, MD, MS, FACP, FIDSA  
Professor of Medicine  
Chief, Adult Clinical Studies  Center for Vaccine Development and 
Global Health (CVD)  
University of Marylan d School of 
Medicine  
685 W. Baltimore St., Suite 480  
Baltimore, MD 21201  
(410) 706 -5328 office  
(410) 706 -1188 direct  
(410) 706 -6156 research concerns  
(410) 706 -6205 fax  
wchen@som.umaryland.edu  
 
 
 
 
 
 
 
 
Lumen Bioscience, Inc.  Confidential  Page 14  
3. Schedule  
 
Lumen Bioscience, Inc.  Confidential  Page 15  Screening  Inpatient    Follow -up 
Day -60 to 
0 -21 to 0  1 2 3 4 5 6 7 8 9 10 11 12 13 14 17 24 31 38 59 87 115 190 
Event  Screen  Screen  Admit   Challenge                     
Window (days)                  ± 2 ± 2 ± 3 ± 3 ± 3 ± 7 ± 7 ± 
30 
Informed consent  X                        
Comprehension 
test (X)                        
Inclusion/exclusion   X X                      
Medical/Surgical 
history, 
comorbidities  X  X                      
Concomitant  
medications  X X X X X X X X X X X X X X X X X X X X X X X  
Campylobacter 
prior -exposure test  
(IgA titer to C. 
jejuni  glycine 
extract )  
X                        
Urine tox  screen  X  X               X       
Collect blood for 
IgA and HLA -B27  
X                        
Collect blood for 
HbsAg, HCV, HIV   X                       
Serum/urine 
pregnancy test1  X X               X       
Collect whole blood 
for hematology3  X X         X      X       
Collect serum for 
chemistry 3  X X         X      X       
Collect blood for 
PT, PTT3  X                X       
Physical 
examination 
(focused PE)   X X X X X X X X X X X X X   (X) (X) (X) (X) (X) (X) (X)  
Vital signs  X X X X X X X X X X X X X X   X X X X X X X  
Electrocardiogram10  X          X             
Height/weight   X X                      
TID dosing of study 
drug13   X X X X X X X X X X X X X X         
Approximate unit 
discharge day7              X           
Review 
memory/diary card    X X             X X       
Campylobacter  
challenge      X                    
Serum for drug 
concentrations2   XX   X   X   X      X       
Lumen Bioscience, Inc.  Confidential  Page 16  Screening  Inpatient    Follow -up 
Day -60 to 
0 -21 to 0  1 2 3 4 5 6 7 8 9 10 11 12 13 14 17 24 31 38 59 87 115 190 
Event  Screen  Screen  Admit   Challenge                     
Collect serum for 
anti-drug 
antibodies   X               X       
Collect serum for 
biomarkers9   X   X X X X X X X             
Collect stool for 
biomarkers9   X   X X X X X X X             
Blood culture for  
T ≥ 39°C       X X X X X X X X X           
Collect s tool for 
weighing and 
grading     X X X X X X X X X X           
Collect stool for 
Campylobacter  
culture5     X X X X X X X X X X   X X X X X X (X)  
Administer 
antibiotics6      (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X)         
AEs8   X X X X X X X X X X X X   X X X X X    
SAEs    X X X X X X X X X X X X   X X X X X X X X 
AESI assessments8                  X X X X X X X 
Telephone Follow 
up/ Study 
completion                         X 
Lumen Bioscience, Inc.  Confidential  Page 17  
1Serum beta -hCG or urine pregnancy test must be collected from women of childbearing potential within 14 days 
before  receipt of first dose of investigational product an d at Day 1. Serum beta -hCG is also collected on Day 24. 
2Serum PK is collected before first dose of study drug; 2 ± 1 hours after first dose of study drug . Serum PK is also 
collected on Day 4; Day 7; Day 10; and Day 2 4.  
3Selected clinical laboratory studies to include hemoglobin, platelet count, white blood cell count with 
differential, sodium, potassium, calcium, magnesium, phosphate, creatinine, aspartate aminotransferase (AST), 
alanine aminotransferase  (ALT), alkaline phosphatase, and total bilirubin. Coagulations studies are prothrombin 
time (PT) and partial thromboplastin time (PTT).  
5Stool culture for Campylobacter  jejuni  collected daily while in study center and at follow up clinic visits. If subje ct 
is not able to produce a sample on the planned Recrudescence  day of the follow -up visit, then the visit should 
be postponed to a day within the window for that visit (e.g., + 2 days) ; if patient still cannot produce a sample, 
then a rectal swab may be taken. If there is no new recrudescence on Day 87 then no stool will be collected for 
Campylobacter  jejuni  culture on Day 115. If there is a new recrudescence on Day 87 then all subjects  who have 
not recrudesced will have a Campylobacter  jejuni  stool culture completed on Day 115.  
6Azithromycin 500 mg po daily and ciprofloxacin 500 mg po twice daily for five days will begin when a subject 
meets early treatment criteria or it has been 144 h ours since the Campylobacter  jejuni  challenge, whichever is 
earlier.  
7Subjects will be discharged from the clinical research facility when they have had 3 days of antibiotics, all 
symptoms have resolved or are resolving, and subjects have had ≥ 2 stool cul tures ≥ 12 hours apart negative for 
C. jejuni  and are afebrile  > 24 hours prior to release and off antipyretics within 24 hours of discharge.  
8Specific solicited adverse events following Campylobacter  jejuni  challenge include diarrhea, fever, nausea, 
vomiting, abdominal pain, abdominal cramping, tenesmus, mucoid or blood y stools,  constipation, headache,  
lightheadedness,  fatigue, lack of appetite, muscle aches, chills, and joint pains  will be monitored through Day 24. 
Subjects will be provided a diary card/memory aid and thermometer for follow -up monitoring of specific solicited 
adverse events. Adverse events will be collected through Day 59. Adverse events of special interest (AESIs) 
following Campylobacte r jejuni  challenge include signs or symptoms of Guillain -Barre syndrome, 
neurodegenerative changes, uveitis, reactive arthritis, and myocarditis/pericarditis and will be collected through 
Day 190.  
9Biomarkers (e.g., serum C -reactive protein, fecal total protein, fecal calprotectin, fecal lipocalin, fecal 
myeloperoxidase, fecal neopterin, fecal lactoferrin, fecal cytokines and/or fecal microbiome). Serum for 
biomarkers will be collected at  aliquoted, and frozen on admission and on Days  4, 5, 6, 7, 8, 9, and 10 . Stool for 
biomarkers will be collected on admission prior to challenge, and on Days 4, 5, 6, 7, 8, 9, and 10 ; the inability of a 
subject to produce a sample on these days will not be considered a protocol deviation.  
10Electrocard iogram at screening and Day 1 0. 
Note : Failure to produce a stool on a specific day for any form of analysis will not be considered as a deviation from the  
protocol. Rectal swabs may be obtained if a subject is unable to produce a stool on the designated  day (see footnote 5).  
 
Lumen Bioscience, Inc.  Confidential  Page 18 4. Introduction  
4.1 Background  and study rationale  
Diarrhea remains a major cause of mortality and morbidity globally, and this is particularly true in 
children under five (Troeger  et al.  2018) . Death is due not only to the primary disease itself, but from 
dehydration and in creased susceptibility to other infectious diseases. Campylobacter jejuni  (C. jejuni)  is 
one of the most common pathogens responsible for these diarrheal disea ses. 
Campylobacter  cause s more than 1.5 million illnesses each year  in the U.S.  (CDC 2017) , mostly due to 
raw or undercooked poultry . Complications can include Guillain -Barré syndrome , irritable bowel 
syndrome (5 -20%), reactive arthritis (1 -5%), erythema nodosum, glomerulonephritis, hemolytic anemia, 
immunoglob ulin A nephropathy, and intestinal perforation . 
Infectious diseases, caused by enteric pathogens, are one of the most common health threats 
encountered by armed forces and cause more lost duty time and operational disruption than combat 
casualties. Militar y personnel are at higher risk because they often must endure environments that are 
conducive to the spread of infectious disease. They are called upon to live in close quarters, travel to 
foreign regions, operate in areas with inadequate sanitation, and live-in situations that force 
compromises to personal hygiene. Infections caused by C. jejuni  have become increasingly common in 
military populations particularly those serving or deployed to Southeast Asia and the Middle East. An 
additional potential preve ntive measure for C. jejuni  infection would be beneficial.  
One possible prevent ion strategy for  Campylobacter  disease involves the use of small therapeutic 
proteins similar to antibodies made by camels, llamas, and alpacas. Like all antibodies, these prote ins 
can recognize and bind to molecules  on patho logic  antigens . The antigen -binding domains of these 
proteins , called variable heavy homodimers (VHHs), can be produced safely in standard biotechnology 
platforms. Libraries of VHHs can be screened to identify individual clones that recognize specific 
antigens, including those displayed by enteric pathogens  such as Camp ylobacter . Orally delivered VHHs 
have successfully modified the severity and duration of diarrhea in male infants with rotavirus infecti ons 
(Sarker  et al.  2013) . They have also been demonstrated to prevent pathogenic infections in animal 
models, including piglet models of ETEC infection ( Harmsen  et al.  2006, Virdi  et al . 2013, Virdi  et al.  
2019) and mouse models of rotavirus infection ( Gara icoechea  et al.  2008, Gomez -Sebastian  et al.  2012, 
Günaydin  et al.  2016, Maffey  et al.  2016, van der Vaart  et al.  2006) .  
VHHs are therefore ideal candidates for preventing and treating enteric diseases. However, t he current 
high  cost of manufacturing VHHs has prevented their widespread use to date.  
Lumen Bioscience has discovered and developed a way to rapidly and stably engineer spirulina  
(Arthrospira platensis ), a type of blue -green algae that is cultivated and consumed worldw ide. In 
ongoing work supported by the Bill & Melinda Gates Foundation, Lumen has demonstrated high -level 
expression of VHHs in spirulina . Moreover,  spirulina containing VHHs with specificity against the FlaA 
flagellin protein of C. jejuni  has been shown to  fully protect against Campylobacter  jejuni  challenge in 
two different mouse challenge models developed by researchers at the University of Virginia (Guerrant, 
et al.,  2019, confidential, unpublished data) and the Institute for Research in Biomedicine , Bellinzona, 
Switzerland (Grassi et al.,  2019, confidential, unpublished data).  
Lumen Bioscience, Inc.  Confidential  Page 19 Lumen developed SP1182, a strain of spirulina  that has been stably engineered to express a protein that 
binds and inhibits the F laA filament protein on the flagellum of C. jejuni . The drug, LMN -101, is orally 
delivered whole, dried spirulina biomass (i.e., the active biologic is not purified from the spirulina 
biomass). After spray drying, the spirulina in this biomass is non -viable  (likely due to the elevated 
temperature and the water removal to form the powder) , while the binding activity of the 
campylobacter -binding protein is retained. The drug product consists of the dried powder packaged in 
vegetable -based capsules for oral del ivery.  
One benefit of the dried spirulina biomass is protect ion of  the binding protein from gastric acid and 
proteolytic enzymes during digestion  and from degradation during storage.  The active biologic agent is a 
large (55 kDa) macromolecule not expected  to be systemically absorbed.  
Spirulina was selected as the expression host because it is considered as  Generally Recognized as Safe 
(GRAS)  by the FDA , has a well -understood and non -toxic safety profile from its wide use as a food source 
for humans and ani mals, has been involved in numerous clinical trials with no reports of adverse events 
(AEs), and is highly stable as a spray -dried powder.  
Taken as a whole,  these data provide support for the potential utility for LMN -101 to prevent 
Campylobacter  jejuni  diarrhea.   
4.2 Dosage rationale  
A Phase 1 trial in Australia demonstrated LMN -101 was safe and well tolerated at the planned dose for 
this study, 3000 mg . There were no significant adverse events or significant laboratory abnormalities 
reported during or follow ing the trial. Rates of adverse events, deemed possibly related, were similar 
between the two groups. Reported adverse events were mild and consisted of nausea, abdominal pain, 
diarrhea, gastroesophageal reflux, constipation, pharyngitis, and delayed menst ruation. Laboratory 
evaluation revealed no systemic VHH absorption  (Jester  et al. 2021) . 
Several murine Campylobacter  jejuni  challenge studies have  demonstrated that the spirulina -VHH no-
observed -adverse -effect level  (NOAEL ) was 13.3 mg biomass, equivalent to 665 mg/kg (Guerrant et al, 
2019, confidential unpublished data). The human -equivalent dose (HED) is scaled based on a mg/kg 
conversion (FDA 2005) . The gastrointestinal compartment weight allometrically scales by W0.94, 
approximated as W1.0 (FDA 2005) , yielding a HED of 665 mg/kg or 46.5 grams/dose. Spirulina has an 
extensive safety record in the food and nutritional supplement industries. In addition, numerous clinical 
trials have been conducted with spirulina with no reports of AEs (Karkos  et al.  2011) .  
Lumen estimates the minimal pharmacologically active dose (PAD) as determined by the murine 
preclinical studies using the challenge strain, which was 67 mg/kg (Grassi et al, 2019, confidential 
unpublished da ta). Based on the gastrointestinal compartment weight and adjusting for repeated drug 
administration, the HED is 43 mg/kg, i.e., 3010 mg for a 70 -kg person. The planned dose for this study, 
3000 mg, is substantially below the calculated NOAEL and incorpora tes a safety factor of 15.5 -fold.  
4.3 Controlled human infection C. jejuni  challenge model  
Human challenge studies with Campylobacter  jejuni  were first conducted at the University of Maryland’s 
Center for Vaccine Development using t he challenge strains A3249 or 81 -176 (Black et al. 1988). Strain 
81-176 induced diarrhea at high inoculum doses but was later identified to have several ganglioside 
Lumen Bioscience, Inc.  Confidential  Page 20 mimics (Guerry 2007). Subsequently, the CG8421 strain was identified and found to lack gang lioside 
mimicry as determined by structural analysis and genome sequencing (Poly et al. 2008).  A new model 
with this strain was developed as a collaboration among the Naval Medical Research Center ( NMRC ), 
University of Vermont, and ACE BioSciences, a Danis h biopharmaceutical company working on a 
candidate Campylobacter  vaccine. This was to improve understanding of campylobacteriosis and 
evaluate products designed for primary and secondary Campylobacter prevention. For an initial clinical 
trial, CG8421 was administered to campylobacter -naïve healthy subjects in a dose -ranging in unit  trial 
with a target attack rate of ≥ 75% of subjects meeting a primary endpoint of campylobacteriosis (Tribble 
et al. 2009).  
At least  118 subjects have received an experimental infection with CG8421 (Kirkpatrick et al. 2013, 
Rimmer et al. 201 8, Tribble et al. 2009). This strain has induced moderate to severe diarrhea in the 
majority of volunteers challenged, without serious AEs, bacteremia, or post -infectious sequelae. One 
consideration for the Campylobacter  jejuni  challenge strain is the pote ntial for recrudescent infection 
after apparent clearance from the stool ( Baqar et al, 2010, Lindow et al, 2010, Rimmer et al. 2018).  
5. Objectives and Endpoints  
5.1 Study Objectives  
Comparing those  subjects  receiving LMN -101 versus those receiving a placebo, th e objectives are:  
Primary  
• To evaluate the frequency of solicited and unsolicited adverse events in subjects that received 
LMN -101 compared to placebo  
 
Secondary  
• To evaluate efficacy based on the proportion of subjects with campylobacteriosis in LMN -101 
versus placebo recipients after challenge with Campylobacter jejuni  
• To evaluate efficacy based on the proportion of subjects with specific solicited adverse events in 
LMN -101 versus placebo recipients after challenge with Campylobacter jejuni  
 
Exploratory  
To evaluate in LMN -101 versus placebo  recipients  after challenge with C. jejuni : 
• Duration of campylobacteriosis symptoms  
• Duration of specific solicited adverse events  
• Severity of campylobacteriosis symptoms  
• Severity of specific solicited adverse events  
• Frequency of recurrence of Campylobacter  jejuni  stool shedding  
• Frequency  of recurrence of  campylobacteriosis clinical sympt oms  
• To correlate  severity of illness  with :  
o serum C -reactive protein  
Lumen Bioscience, Inc.  Confidential  Page 21 o fecal total protein  
o fecal calprotectin  
o fecal lipocalin  
o fecal myeloperoxidase  
o fecal neopterin  
o fecal lactoferrin  
o fecal cytokines  
o fecal microbiome  
• To evaluate  systemic absorption of the VHH in LMN -101, and, if VHH is detected in serum, 
pharmacokinetics of the VHH in LMN -101 and formation of serum anti -drug antibodies to the 
VHH in LMN -101 
5.2 Study Endpoints  
The endpoint s will compare LMN -101 to placebo : 
Primary  
• Safety : Frequency of solicited  or unsolicited adverse events  in subjects that received LMN -101 
compared to placebo  for the protocol -specified duration of collection for each type of adverse 
event  
 
Secondary  
• Efficacy : Proportion of subjects with campylobacteriosis  after challenge with Campylobacter 
jejuni strain CG8421  
• Efficacy : Proportion of subjects with specific solicited adverse events after challenge with 
Campylobacter jejuni strain CG8421  
 
• “Camp ylobacteriosis ” is define d as: 
• Moderate to severe diarrhea (≥ 4 l oose stools or ≥ 401 g of loose stools in 24 hours); 
or 
• Fever (oral temperature ≥ 38.0°C present on at least two occasions, at least 20 
minutes apart) plus at least one of the following  symptom s of moderate severity:  
nausea, vomiting, abdominal cramps , ten esmus; or 
• Fever (oral temperature ≥ 38.0°C present on at least two occasions, at least 20 
minutes apart)  plus gross blood in ≥ 2 loose stools  
• “Specific solicited adverse events” is defined as  
o diarrhea,  
o fever,  
o nausea,  
o vomiting,  
o abdominal pain,  
o abdominal cramping,  
o tenesmus,  
o mucoid or bloody stools,  
o constipation,  
o headache,  
o lightheadedness,  
Lumen Bioscience, Inc.  Confidential  Page 22 o fatigue,  
o lack of appetite,  
o muscle aches,  
o chills , 
o joint pains  
 
Exploratory  
• Efficacy : 
o Duration  of diarrhea , diarrhea amount (total weight ) and stool grad e 
o Duration of campylobacteriosis symptom s 
o Duration of specific solicited adverse events  
o Severity of campylobacteriosis symptoms  
o Severity of specific solicited adverse events  
o Frequency of recurrence of Campylobacter  jejuni  stool sheddi ng 
o Frequency  of recurrence of campylobacteriosis clinical symptoms  
o Correlation of biomarkers with severity of illness, including serum C -reactive protein, fecal 
total protein , fecal calprotectin, fecal lipocalin, fecal myeloperoxidase, fecal neopterin, fec al 
lactoferrin, fecal cytokines, and/or fecal microbiome  
• Pharmacology : 
o Detection of measurable VHH in serum  
o If measurable VHH in serum is detected at any timepoint, then assays to measure the 
following will be performed:  
Peak serum VHH concentration following administration of the initial dose and peak serum VHH 
concentration following a course of treatment  
Area under the serum VHH concentration versus time curve (AUC) following administration of the 
initial dose and following a course of treatment  
Induction of serum anti -VHH IgG antibodies  
6. Study Design  
6.1 General Schema of Study Design  
Randomized, double -blind, placebo -controlled, single dose study of LMN -101 followed by 
Campylobacter challenge. The trial will be evalu ated based upon a cohort of 21 active and 21 placebo 
subjects in cohort sizes as determined by the trial site. After the initial cohort has completed the in-
center  portion of the study, an unblinded statistician  will perform an interim analysis .  
6.2 Study Dur ation, Enrollment, and Number of Sites  
Estimated duration for the main protocol ( e.g.,  start of screening through final subjects finishing the 
study) is approximately 9 months. Subjects will be screened for eligibility a maximum of two months 
prior to the start of the treatment phase . The treatment phase will last 14 days  and will be followed by a 
6 month follow -up phase . A maximum of 2 00 subjects will be enrolled and screened to obtain 
approximately 60 eligible subjects  to ensure 42 total subjects are available to be treated  (21 active, 2 1 
placebo).  
Lumen Bioscience, Inc.  Confidential  Page 23 The study center will be Pharmaron Clinical Research Center in  Baltimore, Maryland .  
6.3 Risks/ benefits  
Naturally acquired  illness  caused  by Campylobacter  jejuni  ranges from mild  to severe wa tery diarrhea 
that may contain mucus or blood.  Nausea, vomiting, abdominal cramping, headache, abdominal  gurgling  
or gas, anorexia,  fever,  muscle  and/or  joint  aches,  and malaise may occur. Rarely, events of myocarditis, 
pericarditis, and myopericarditis have been reported following C. jejuni  infection. For most adults, the 
illness is not life -threatening but often leads to mild -to-moderate dehydration and significant 
inconvenience associated  with loss of sleep and activity. Recrudescence of Campylobacter  jejuni  
infection  is also a risk . Study facilities will have personnel and resources capable to manage diarrheal 
illness and potential complications. Side effects of  the antibiotics  (azithromy cin and ciprofloxacin)  used  
to treat  the Campylobacter  jejuni  infection  are possible.  
Spirulina has a well-described  safety  profile. However, possible non -serious side effects have been 
reported with spirulina intended as a nutritional supplement. The FDA MedWatch from January 2001 to 
July 2009 identified the most common non -serious adverse events from spirulina were nausea, diarrhea, 
vomiting, fatigue, headache, dizziness, itching, rash, and abdominal cramps. These reports lacked 
information on the quantit y, duration, individual  history , or quality of spirulina used  and were based on 
non-GMP spirulina  (Marles  et al.  2011) .  
Therapeutic antibiotics  for use in this study are licensed approved medications that have been used 
extensively and shown to be very  safe with  only  rare side effects.  The most  commonl y reported side  
effects  for ciprofloxacin  are gastrointestinal  symptoms  (nausea,  vomiting,  and diarrhea) in as many as 5 
individual s in 100. Other reported symptoms in less than 1 individual  in 100 include rash, dizziness, and 
headache. Rarely, allergic reactions to these medications have been observed. Ciprofloxacin is not 
recommended for  use in pregnancy due to  concerns of joint damage to the unborn child (based on 
studies in young animals).  Pregna ncy is exclusionary for study participation and  is documented  through  
testing prior to  study interventions  and provided  discussion  on methods  to prevent  pregnancy  during 
study.  Fluoroquinolones, including ciprofloxacin, are associated with an increased ris k of tendinitis and 
tendon rupture in all ages. The risk of developing fluoroquinolone -associated tendinitis and tendon 
rupture is further increased in individual s over 60 years of age, in individual s taking corticosteroid drugs, 
and in individual s with ki dney, heart, or lung transplants, all of whom are either not included or 
specifically excluded from this study . Ciprofloxac in can rarely prolong the QT interval, so an ECG is done 
at screening to ensure that there is no pre-existing QT prolongation . Clostr idium difficile -associated 
diarrhea (CDAD/ pseudomembranous colitis) has been reported with use of nearly all antibacterial 
agents.  
The most common adverse events in response to azithromycin are vomiting, diarrhea, nausea , or 
abdominal pain.  Azithromycin  can rarely prolong the QT interval, so an ECG is done at screening to 
ensure that there is no pre-existing QT prolongation . 
If the subject does not tolerate azithromycin or ciprofloxacin, the subject  will be given an alternative 
antibiotic (either amoxici llin-clavulanate or cefpodoxime).  The most common amoxicillin -clavulanate 
side effects may include nausea, vomiting, or diarrhea; rash or itching; vaginal itching or discharge; or 
Lumen Bioscience, Inc.  Confidential  Page 24 diaper rash. The most commonly reported side effects for cefpodoxime include  oral candidiasis, 
abdominal cramps, diarrhea, nausea, and vomiting.  
Good nursing practice  will be utilized  during  blood  draws,  which  minimizes the  risk to the subject.  
Handwashing and sanitary  disposal  of feces  (including  pretreatment  with  bleach)  are th e main  elements  
of personal  hygiene  and will minimize  the spread  by person -to-person infection; handwashing will be 
emphasized to the  subjects , and subjects  will be instructed  not to share food or beverages. Subjects and 
staff will be trained in proper techniques of handwashing. Subjects will be instructed as to  the 
importance  of completing  the 5-day course of antibiotics , and this instruction will be documented. Risk 
of secondary transmission is hi ghly unlikely due to antibiotic treatment and because  subjects are 
required  to submit  two confirmed  negative  stool samples prior to discharge.  
A less common, but potentially life -threatening, complication of C. jejuni infection is Guillain -Barré 
syndrome ( GBS), a post -infectious polyneuropathy that is a leading cause of paralysis, and the related 
syndrome Miller -Fisher syndrome  (Heikema  et al.  2013, Keithlin  et al.  2014) . Although many infectious 
agents are associated with GBS, C. jejuni is the most frequent pathogen associated with the syndrome  
(Baker  et al.  2012) . The association between GBS and  Campylobacter  jejuni  infection is supported by 
serologic, culture, and experimental data. Published data from a large case -control study of 
campylobacter -associated GBS showed evidence of C. jejuni  infection in 26% of the 103 GBS and Miller -
Fisher syndrom e patients compared to 2% of household controls, and 1% of hospital controls (Rees  et al.  
1995) . The pathogenesis of GBS following Campylobacter  jejuni  infection i s hypothesized to involve 
“molecular mimicry,” where peripheral nerves share epitopes with some C. jejuni antigens (Godschalk et 
al. 2004) . Thus, an immune response, which is initially mounted against the infection, may be 
misdirected to peri pheral nerves in some convalescing individual s. Based on this knowledge, a detailed 
characterization of strain CG8421 documented the lack of ganglioside mimicry and therefore posed no 
risk of GBS or Miller -Fisher syndrome (Poly et al.  2008) . 
Like Salmonella , Shigella , and Yersinia , Campylobacter  jejuni  enteritis has been associated with 
development of a reactive arthritis/arthropathy (RA)  (Ajene et al, 2013) . This risk is increased in 
individuals who have the HLA -B27 antigen. All subjects will be screened for HLA -B27, and a positiv e 
result will be an exclusion criterion for the study.  
There is a risk of functional bowel disorders, including irritable bowel syndrome, following 
Campylobacter  jejuni  enteritis  (Riddle et al, 2012) .  
There is a minimal risk of pain, hematoma, or infection at the site of  venipuncture.  The maximum  
amount of blood drawn from a subject in total, and daily, will fall within applicable regulations.  
There may be physical, psychological, and social risks if  subjects  test positive  for hepatitis  B, hepatitis C, 
and/or HIV. Subjects testing positive will be counseled and referred for treatment.  
Medical records associated with this protocol  are subject to provisions of the Privacy Act of  1974, 5 
U.S.C., Section 552A, and AR 34 0-21. All data and medical information obtained about subjects will be 
considered privileged and held in  confidence.  Subjects will  not be identified by name in any published 
report/presentation  of the results.  Complete confidentiality  cannot  be promised to  individual subjects 
who are military personnel because appropriate medical command authorities may require reporting 
information bearing  on the health  of their  personnel. Representatives of the Sponsor, investigational 
Lumen Bioscience, Inc.  Confidential  Page 25 site IRB, or FDA may inspect the rec ords  of this research as part of  their  responsibility  to oversee  
research  and ensure  protection  of subjects. Study results and data may be published in 
scientific/medical journals; the  identity  of individual subjects will not be disclosed.  
7. Study Population  
7.1 Recruitment, screening, and enrollment of study volunteers  
Volunteers will be recruited using standard procedures for Pharmaron clinical trials. All study -related 
advertisements will be reviewed and approved by the IntegReview IRB. Subjects who express interest in 
participating in the study will be asked to complete a n IRB -approved  pre-screen  questionnaire by 
telephone  to assess general health status and basic eligibility. A maximum of 200 potential volunteers 
determined to be generally healthy a nd meeting basic eligibility requirements will be scheduled for an 
in-person screening. Volunteers for challenge studies are carefully screened on the details of the 
protocol, their time commitment, and the nature of the confinement on a quarantine ward. During  the 
in-person screening , volunteers will take a test to make sure that they understand the study and its 
requirements.   
Informed consent is a  continuous process  that includes  the written subject informed  consent  document.  
Subjects will receive an ora l presentation of the study  in language  they can understand  (i.e.,  using  lay 
terms  as appropriate) . Each prospective subject will be given the written, IRB -approved informed 
consent, allowed ample time to read the consent, allowed to ask  questions  about  the study,  have 
his/her questions answered, and  given  time  to decide  if he/she  would  like to participate  in the study.  To 
document subject’s  understanding of informed  consent, immediately  before  the consent is  signed,  the 
person  obtaining  consent  will administer  a brief  quiz or comprehension test. Incorrect answers will be 
discussed with subjects  to reinforce  the consent  and subjects  will be given one additional opportunity to 
take the test. A final acceptable test score is 70% or more answered correctly. Subjects failing after two 
attempts are not eligible for study enrollment. No coercion or influence is allowed in obtaining subject ’s 
consent.   
Before subjects participate in  any study -related activity , including procedures to determine eli gibility, 
consent forms will be signed and dated by subjects  as well as by the PI or designee. Subjects will receive 
copies of the signed consent pr ior to participation. As part  of the consent process, subjects will also be 
asked to read and sign a Medical Records/Lab Results  Release,  and other IRB -approved  study  
documents,  and will be provided  with  an opportunity  to ask questions.  
7.2 Inclusion Criteria  
1. Male or non-pregnant female between 18 and 50 years  of age , inclusive, at time of informed 
consent  
2. Willingness to participate after written informed consent obtained  
3. Available for all planned clinical visits (for physical examinations, blood draws, and stool 
collections) and follow -up monitoring (9 or 10 clinic visits  and 1 phone interview  6 months post -
challenge)  
4. Agreement to follow the restrictions of the study. Willing and able to follow the study directions 
and procedures, including the rules and procedures of the clinical research  unit.  
Lumen Bioscience, Inc.  Confidential  Page 26 5. Demonstrated comprehension of the protocol procedures  including knowledge of Campylobacter 
illness  by passing a written examinatio n (passing grade ≥ 70%) . 
6. General good health, without significant medical illness or abnormal physical examination 
findings as determined by the PI.  
7. Laboratory values are Grade 1 or lower using the Common Terminology Criteria for Adverse 
Events (CTCAE) Ver sion 5.0  as defined below : 
a. Absolute neutrophil count ≥ 1500 /µL  
b. Lymphocyte count ≥ 800/µL  
c. Platelet count ≥ 125,000/µL   
d. Hemoglobin ≥ 13.0  g/dL  in males ( ≥ 11.0  g/dL in females)  
e. Serum creatinine ≤1. 5x ULN  
f. ALT and/or AST ≤ 1.5x ULN  
g. Total bilirubin ≤ 1.5x ULN  
8. Females of childbearing potential must  commit to use one of the following  highly effective 
methods of  birth control  consistently for at least 1 month prior to screening through study 
completion:  
a. Stable hormonal contraception  with inhibition of ovulation ; or  
b. Intrauterine device (IUD); or  
c. Bilateral tubal occlusion ; or 
d. Surgical sterilization (vasectomy) of  male partner at least 6 months prior to study ; or 
e. Sexual abstinence (inactivity) . 
9. To be considered of non -childbearing potential, females should be surgically sterilized (bilateral 
tubal  ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be 
post -menopausal and at least 1 year since  menses  with follicle -stimulating hormone ≥ 40 u nits. 
10. Males should  use condoms for contraception and refrain from donating sperm through Day 64.  
11. BMI between 18.5 and 33.5 inclusive  
12. Complies with current Pharmaron Covid -19 policies and procedures  
 
7.3 Exclusion Criteria  
1. Significant medical condition or laboratory abnormalities that in the opinion of the Principal 
Investigator preclude participation in the study.   
2. History of Covid symptoms or positive Covid test within 2 weeks prior to admission date . 
3. Alcohol or illicit d rug abuse/dependency  
4. Positive serology results for HIV, HBsAg, or HCV with confirmatory assays.  
5. Pregnancy or breastfeeding  
6. Personal or documented family history of Guillain -Barré syndrome or neuromuscular disease; or 
an inflammatory arthritis such as rea ctive arthritis, ankylosing spondylitis, or rheumatoid 
arthritis; inflammatory bowel disease; autoimmune disease; malignancy (not including basal cell 
carcinoma); any immunocompromising condition; or history of major gastrointestinal surgery.  
7. Evidence of n eurological abnormalities.  
8. History of reactive arthritis or evidence of inflammatory arthritis on exam.  
9. Fever within the 2 weeks prior to time of enrollment.  
10. Evidence of IgA deficiency (serum IgA < 7 mg/mL or below the limit of detection of assay).  
11. HLA-B27 positive  
Lumen Bioscience, Inc.  Confidential  Page 27 12. Allergy or prior intolerance to two or more of the following antibiotics: azithromycin, 
ciprofloxacin, levofloxacin, erythromycin, ampicillin, or amoxicillin/clavulanate.  
13. Allergy or prior intolerance to spirulin a or spirulina products . 
14. Fewer than  3 stools per week or more than 3 stools per day as the usual frequency.  
15. History of moderate to serious diarrhea while traveling in a developing country within the last 3 
years.  
16. History of myocarditis or pericarditis .  
17. History of major abdominal surgery or  unexplained abdominal scar. Ok if appendectomy or 
cholecystectomy (one year post)  
18. Regular use of antidiarrheal, antacids, loperamide, bismuth subsalicylate diphenoxylate, or 
similar medication affecting bowel motility (regular defined as at least weekly).  
19. Use of proton pump inhibitors, H2 blockers, or other antacids within 48 hours preceding 
initiation of LMN -101 or placebo.  
20. Use of antibiotics during the 7 days preceding initiation of LMN -101 or placebo.  
21. Use of spirulina, or spirulina containing products, other than the study drug in the 30 days 
preceding initiation of LMN -101 or placebo.  
22. Use of any investigational product within 30 days preceding initiation of LMN -101 or placebo or 
planned use during the active study period.  
23. Use of any medication known to affect the immune system (e.g., systemic corticosteroids, 
chemotherapy , mono clonal a ntibody biologic response modifiers ) within 12 months preceding 
initiation of LMN -101 or placebo or planned use during the active study period (excluding 
inhaled steroids with spacer).  
24. History of prior exposure to Campylobacter including by vaccination or infection in previous 
trials, or serum immunoglobulin A (IgA) titer to C. jejuni  glycine extract >1: 4000.  
25. Other dietary or environmental exposures that may place the subject at high risk for prior 
Campylobacter exposure (to be determined on a case -by-case basis by the PI).  
26. Employment as a food handler; childcare worker; or caregiver for elderly, immunocompromised 
individuals, or other at -risk population.  
27. History of major mental illness such as schizophrenia, major depression or suicidal ideation  
28. Any other c riteria which, in the Principal Investigator’s opinion, would compromise the ability of 
the subject to participate in the study, the safety of the study or the results of the study.  
29. Potential participant’s 12 – lead electrocardiogram demonstrating patholog ic abnormalities 
including non -sinus rhythm, pathologic Q waves, significant ST -T wave changes, corrected QT 
interval (QTc) using Fridericia correction (QTcF) at screening and Day -1 (admission) >450 msec.  
30. At screening , systolic blood pressure >140 mm Hg  or diastolic blood pressure >90 mm Hg.  
8. Study Schedule  
8.1 Screening (Two months prior to study start)  
Subjects will be screened for enrollment within two months before Day 1. Subjects will be screened 
according to predefined inclusion criteria as described in section 7.2. See section 7.3 for a list of exclusion 
criteria. The following procedures will be performed at screening:  
• Informed Consent  
Lumen Bioscience, Inc.  Confidential  Page 28 • Comprehension test  
• Medical history, including existing medical conditions  
• Record concomitant medications  
• Vital signs in cluding heart rate, respiratory rate, blood pressure , and temperature  
• Campylobacter prior exposure test  
• Urine toxicology screen  
• Collect blood samples for immunoglobulin and HLA -B27 tests  
8.2 Study -Specific Screening (Three weeks prior to start)  
Note: Study team will have flexibility to perform screening and study -specific screening procedures at any 
point prior to admission to research clinic  
Visit will include the following procedures:  
• Assessment of inclusion/exclusion criteria  
• Record concomitant med ications  
• Collect blood samples for Hepatitis B, Hepatitis C, and HIV tests  
• Serum or urine pregnancy test for female subjects of childbearing age  
• Selected clinical laboratory studies to include hemoglobin, platelet count, white blood cell count 
with differe ntial, sodium, potassium, calcium, magnesium, phosphate, creatinine, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and total bilirubin. 
Coagulations studies are prothrombin time (PT) and partial thromboplastin time  (PTT).  
• Physical examination  
• Vital signs  
• Electrocardiogram  
• Height/weight  
8.3 Treatment Phase  
Day 1 : Admission to research clinic  
Assessment of inclusion/exclusion criteria  
Medical history, including existing medical conditions  
Record concomitant medications  
Urine toxicology screen  
Serum or urine pregnancy test for female subjects of childbearing age  
Selected clinical laboratory studies to include hemoglobin, platelet count, white blood cell count with 
differential, sodium, potassium, calcium, magnesium, phos phate, creatinine, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and total bilirubin.  
Physical examination  
Height/weight  
Collect serum for anti -drug antibodies  
Collect serum for drug concentrations  
Collect stool sample  
Subjects will receive three doses of their assigned IP throughout the day  
While in unit, doses will be co -administered with 50 mL of bicarbonate buffer  
Subjects will be monitored for at least 60 minutes for any AEs, SAEs, or allergic reactions, then have a 
set of vital signs taken.  
Subjects will be given a diary and thermometer and instructed on use  
Lumen Bioscience, Inc.  Confidential  Page 29  
Day 2   
Record concomitant medications  
Physical examination  
Subjects will receive three doses of their assigned IP throughout th e day  
While in unit, doses will be co -administered with 50 mL of bicarbonate buffer  
Subjects will be monitored for at least 60 minutes for any AEs, SAEs, or allergic reactions, then have a 
set of vital signs taken.  
Staff will collect and review the diary w ith the subject s 
 
 
Day 3: Challenge day  
Subjects will consume a light breakfast and fast for 90 minutes before the challenge procedure. Sixty 
minutes into the fast, they will take a dose of IP with 50 mL USP -grade bicarbonate buffer solution then 
continue  to fast. At 90 minutes, subjects will drink 120 mL of USP -grade bicarbonate buffer solution, 
followed approximately 1 minute later with the C. jejuni  CG 8421 strain challenge, 5 x 105 CFU. Subjects 
will be observed, and vital signs measured approximately 30 minutes after dosing. Subjects will fast for 
an additional 90 minutes after receiving the challenge. Subjects will receive afternoon and evening 
doses of IP. The following procedure s will also be performed:  
Subjects will be monitored for AEs , specific solicited AEs,  and SAEs  
Record concomitant medications  
Physical examination  
Vital signs including additional vital signs 30 minutes after challenge  
Collect, weigh , and grade stool samp le  
Collect stool sample and culture for presence of C. jejuni   
 
Day 4 - Day 9 
Clinical research staff will monitor the subject’s general and gastrointestinal health, assess systemic signs 
and symptoms, and determine any adverse events by medical interview and focused physical 
examinations. Additionally, subjects will be examined for  symptoms and signs of dehydration.  
The following procedures will be performed:  
Collect serum for drug concentrations on Day 4 and Day 7  
Start antibiotic treatment at 144 hours after challenge or when they meet early treatment criteria, 
whichever is earli er. Azithromycin 500 mg po daily and ciprofloxacin 500 mg po twice daily for five 
days . 
 
The following procedures will be performed daily  (hereafter “daily procedures”) : 
Subjects will be monitored for AEs , specific solicited AEs,  and SAEs  
Record concomitant medications  
Physical examination  
Vital signs  
Subjects will receive three doses of their assigned IP co-administered with 50 mL of bicarbonate 
buffer throughout the day  
Collect serum for biomarkers  
Lumen Bioscience, Inc.  Confidential  Page 30 Collect stool for biomarkers  
Collect, weigh , and grade stool sample  
Collect stool sample and culture for presence of C. jejuni   
Blood culture for temperatures ≥ 39°C  
 
Day 10 
Perform daily procedures  
Selected clinical laboratory studies to include hemoglobin, platelet count, white blood cell count w ith 
differential, sodium, potassium, calcium, magnesium, phosphate, creatinine, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and total bilirubin.  
Collect serum for drug concentrations  
Electrocardiogram  
Review dis charge criteria  
 
Day 11 - Day 12  
Subjects will be monitored for AEs, specific solicited AEs, and SAEs  
Record concomitant medications  
Physical examination  
Vital signs  
Subjects will receive three doses of their assigned IP co -administered with 50 mL of bicarbonate 
buffer throughout the day  
Collect, weigh, and grade stool sample  
Collect stool sample and culture for presence of C. jejuni   
Blood culture for temperatures ≥ 39°C   
Review discharge criteria  
 
Discharge Day  
Subjects will be discharged from the research clinic when the following criteria are met:  
at least three  days after commencing antibiotics;  
when all symptoms have resolved or are resolving;  
subjects have had ≥ 2 consecutive stool cultures ≥ 12 hours apart negative for C. jejuni . 
Subjects wil l receive remaining antibiotics and  remaining  IP doses to take at home  
Subjects will take home a diary card/memory aid and thermometer to monitor for solicited adverse 
events , including diarrhea, fever, nausea, vomiting, abdominal pain, abdominal cramping,  mucoid or 
bloody stools, headache, fatigue, lack of appetite, muscle aches, chills, and joint pains.  
 
Day 17 ± 2 days  
Assess for AEs and SAEs  
Record concomitant medications  
Physical examination  
Vital signs  
Review subject’s diary  
Collect stool sample and culture for presence of C. jejuni  
Lumen Bioscience, Inc.  Confidential  Page 31 8.4 Follow -up Phase  
The following procedures will be performed during follow -up visits (hereafter “follow -up visit 
procedures”):  
Assess for SAEs and AESI  
Record concomitant medications  
Collect stool sample and culture for presence of C. jejuni   
Vital signs  
 
Day 24 ± 2 days  
Follow -up visit procedures  
Assess for AEs  
Urine toxicology screen  
Serum or urine pregnancy test for female subjects of childbearing age  
Selected clinical laboratory studies to include hemoglobin, platelet count, white blood cell count with 
differential,  sodium, potassium, calcium, magnesium, phosphate, creatinine, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and total bilirubin. 
Coagulations studies are prothrombin time (PT) and partial thromboplastin time (PTT) . 
Review subject’s diary  
Collect serum for drug concentrations  
Collect serum for antidrug antibodies  
 
Day 31 (± 3 days)  
Follow -up visit procedures  
Assess for AEs  
 
Day 38 (± 3 days)  
Follow -up visit procedures  
Assess for AEs  
 
Day 59 (± 3 days)  
Follow -up visit procedures   
Assess for AEs  
 
Day 87 (± 7 days)  
Follow -up visit procedures  
 
Day 115 (± 7 days)  
Follow -up visit procedures  
 
Day 190 (± 30 days)  
Research clinic staff will call subjects approximately six months following challenge. SAEs and AESIs will 
be assessed and recorded.  
Lumen Bioscience, Inc.  Confidential  Page 32 8.5 Recrudescent infection and recrudescent follow -up plan  
Monitoring for  C. jejuni  recrudescence utilizes clinical and microb iological active surveillance. Post -
discharge clinic visits (with stool culture collection) will occur approximately on Days 17, 24, 31, 38, 59, 
and 87 (14-, 21-, 28-, 35-, 56-, and 84 -days post  challenge). Stools will be cultured to determine the 
presence  of Campylobacter  jejuni  organisms. As with the initial clinic  visits, if a subject fails to produce a 
stool on the planned day of a  follow -up visit then the sample collection should be postponed to a day 
within the window for that visit (e.g., ± 2 days). If they still cannot produce a sample, then a rectal swab 
may be taken.  
In the event of a recrudescence in any subject by Day 87, all subjects still on study who have not 
recrudesced will be contacted to attend a further visit with stool collection on Day 115 (± 4 days). If 
there is no recrudescence in any subject by day 87 then the day 115 visit will not be required.  
Recrudescence of infection : Defined as positive stool culture for the C. jejuni strain used for inoculation 
occurring after a complete course of antibiotics, clinical improvement, and clearance of stool cultures (a 
minimum of 2 C. jejuni  culture negative stool specimens at least 12 hours apart ).  
Prior studies, using the same C. jejun i strain, have demonstrated that between 4 -18% of subjects 
receiving the investigational inoculum experienced a recrudescence of Campylobacter  jejuni  infection. 
The recrudescence events were detected and confirmed as strain CG8421 through tests on stool 
specimens obtained at clinic visits, despite > 2 negative stool cultures for C. jejuni prior to discharge 
from the clinical research  unit. In all cases but one, additional antibiotics (azithromycin and ciprofloxacin 
for 10 days) were provided, and the infect ion was cleared. One subject cleared , however , experienced a 
second recrudescence. This volunteer was lost to follow -up prior to completing enhanced follow -up 
schedule.  
Recrudescent follow -up plan  
If a recrudescent event occurs , the subject will be assess ed as soon as possible with a medical interview  
and physical examination. The subject will be followed for a total of 6 months from the date of 
documented infection recurrence. The date of production of the stool demonstrating recrudescence will 
be re -designated as Recrudescence Day  0 for follow -up purposes.  
Recrudescent f ollow -up will include:  
Medical interview and physical examination as soon as possible.  
Repeat stool collection will occur with testing for stool microbiology and expanded to include routine 
C. difficile , stool bacteriology and parasitology if the subject has symptoms. The subject will be tested 
for evidence of immunocompromise; hypogammaglob ulinemia testing and a repeat HIV test will be 
performed.  
The strain will be confirmed by clinical microbiology and PCR testing to confirm it is the study strain. 
The C. jejuni  isolate will be tested to ensure continued antibiotic susceptibility.  
Combinat ion antibiotic treatment with ciprofloxacin 500 mg po BID and azithromycin 500 mg po QD 
will be given for a total of 10 days.  
If a subject experiences side effects from the azithromycin and ciprofloxacin therapy requiring an 
alternative agent, another eff ective antibiotic, based on documented challenge strain susceptibility, 
will be used. Alternative antibiotic doses are as follows: amoxicillin/clavulanate (Augmentin) 875 mg 
Lumen Bioscience, Inc.  Confidential  Page 33 PO BID for five days or cefpodoxime 400 mg PO BID for 5 days. The cGMP challenge s train CG8421 
has documented susceptibility to ampicillin by prior testing. Decisions regarding antibiotic use will be 
determined by the study clinician on a case -by-case basis, performed in discussion with the Medical 
Monitor.  
On Recrudescence Days 14, 21,  28, 35, 56, and 84, the subject will undergo a medical interview and 
physical assessment along with stool collection for microbiology. On Recrudescence Days 56 and 84, 
stool will also be collected for exploratory endpoints.  
Follow -up will be completed wi th a telephone interview on Recrudescence Day 190 (± 30 days) to 
inquire about new -onset serious health events.  
If any previously recrudesced subject experiences a second recrudescence prior to Recrudescence Day 
84, that subject will restart the follow up sequence as above.  
8.6 Assessment of subject compliance with investigational products  
A member of the study team will observe  the ingestion of the first dose of investigational product (IP). 
The subject will be given a diary to take home after their discharge to document subsequent doses of 
the IP. While in unit , the subject will be administered the IP, C. jejuni  challenge, and antibiotics under 
direct observation. If subject is to complete the antibiotic course at home, then the subject will be 
questioned rega rding compliance at the next study visit and diary review.  
8.7 Concomitant medications  
Only concomitant medications approved by the study physician will be used during the study. Subjects 
taking regular medication (e.g., birth control pills) prior to enrollmen t will be allowed to continue unless 
it is specifically excluded as part of the inclusion/exclusion criteria. Subjects requiring non -approved or 
excluded medication will not be eligible for enrollment. Any medication ordered during the trial (e.g., 
ondanse tron, acetaminophen, azithromycin, ciprofloxacin, or alternative antibiotics) will be documented 
in source documents and on the appropriate page of the case report forms. Approved medications that 
were being taken prior to  and during  the trial will also be  documented.  
8.8 Early termination  
Subjects have the right to withdraw from the study at any time and for any reason without affecting the 
right to treatment by the Principal Investigator for study -related conditions. The Principal Investigator 
also has the right to withdraw subjects in the event of intercurrent illness, AEs, or for 
administrative/social reasons.  
Should withdrawals occur, efforts will be made to ensure subject safety. In case of subject withdrawal, 
for whatever reason, a final trial evaluatio n must be completed (if possible) stating the reasons. 
Withdrawals due to non -attendance must be followed -up by the Principal Investigator to the extent 
possible to obtain the reason for non -attendance. Subjects withdrawing from the study prior to 
receivin g the challenge dose (Day 3) will stop taking the investigational product and be asked to 
complete a final visit for safety about 28 days (± 5 days) after the last dose. Subjects withdrawing after 
receiving the C. jejuni  challenge dose will receive antibio tics (two days dosing under direct observation 
prior to discharge) for  their own  at-home treatment and will be educated on the importance of 
complying with treatment. Attempts will be made to follow all subjects for safety through Day 190.  
Lumen Bioscience, Inc.  Confidential  Page 34 8.9 Randomization   
Subjects will be randomized in a 1:1 ratio to one of two treatment groups (LMN -101 or placebo) per 
cohort as detailed in the Pharmacy Manual. Subjects who fulfill  all inclusion/exclusion criteria and are 
eligible to participate will be assigned the next seq uential treatment number by the Principal 
Investigator. The treatment number corresponds to a given treatment assignment known to the study 
pharmacist but blinded to the subject, the PI, and the remaining members of the clinical research site 
and collabora tors.  
Sealed, code -break envelopes will be provided to the research pharmacist if a given subject has a serious 
adverse event that requires unblinding of treatment assignment.  
If a given subject drops out of the study or becomes ineligible before the Cam pylobacter  jejuni 
challenge, they will be replaced on the study by a subject given the same treatment assignment.  
8.10 Blinding  
Individual subject assignments to a given treatment group will remain blinded to investigators , subjects , 
and personnel involved in collecting, cleaning, and analyzing the data until completion of the trial phase 
and validation of the clinical and outcome data.  
8.11 Fluid and bacteremia m anagement  
8.11.1  Oral fluid replacement  
Any subject passing grade 3 -5 stools will be  encouraged  to drink fluids at a rate  equal to or greater than 
their stool output. If willing, the volunteers will be provided with Oral Rehydration S olution, as an 
optimal replacement. Other oral fluids may be substituted.  
8.11.2  Criteria for IV fluid replacement  
During the trial, a subject will be considered for intravenous (IV) fluid replacement if determined 
necessary by study physician (e.g., diarrhea with nausea/vomiting and unable to replace by oral route).   
8.11.3  Criteria for serum electrolyte monitoring  
Study physicians will assess the need for testing based on clinical status and previous laboratory results.  
Serum electrolyte levels will be foll owed in any subject who meets criteria for intravenous fluid 
replacement.  
8.11.4  Criteria for blood culture surveillance  
Blood cultures will be collected if a subject has a confirmed temperature of   39.0 °C. The blood culture 
will be processed using standard pra ctices through the Quest microbiology laboratory. If a blood culture 
is positive for Campylobacter , it will be repeated until there are 2 negative sets of blood cultures.  
8.11.5  Management plan for Campylobacter  jejuni  bacteremia .  
Subjects who develop Campylobacter  jejuni  bacteremia will be treated with  empiric  intravenous 
ciprofloxacin  in conjunction  with oral azithromycin.  Intravenous amoxicillin -clavulanate is an alternative 
antibiotic.  Therapy will be modified as indicated based  on antibiotic susceptibility testing of the 
Lumen Bioscience, Inc.  Confidential  Page 35 Campylobacter  jejuni  isolates.  Decisions regarding changes  in antibiotic use will be determined by the 
study clinician on a case -by-case basis, performed in discussion with the Medical Monitor . 
8.12 Planned antibioti c treatment phase  
Antibiotics will be supplied through the study site investigational pharmacy . Azithromycin (500 mg by 
mouth once daily for 5 days) concurrently with ciprofloxacin (500 mg by mouth BID for 5 days) will be 
used as the treatment regimen for  all subjects, unless the study physician or designee determines that 
intravenous  antibiotics are required for a specific participant . The challenge strain  is susceptible to both 
antibiotics. If a recrudescent event occurs, both ciprofloxacin and azithromycin will be given for a total 
of 10 days. If a subject experiences side effects from the azithromycin and/or ciprofloxacin therapy 
requiring an alternative ag ent, another effective antibiotic, based on documented challenge strain 
susceptibility, will be used. Alternative antibiotic doses are as follows:  amoxicillin/clavulanate 
(Augmentin) 875 mg PO BID for five days or cefpodoxime 400 mg PO BID for 5 days. The cGMP challenge 
strain C. jejuni CG8421 has documented susceptibility to ampicillin by prior testing. Decisions regarding 
changes  in antibiotic use will be determined by the study clinician on a case -by-case basis, performed in 
discussion with the Medical M onitor . 
Antibiotic treatment is scheduled to start approximately 144 hours ± 1 -hour post -challenge. Early 
treatment will commence if the following criteria are met : 
8.12.1  Criteria for early treatment with antibiotics  
Subjects meeting any of the following criteri a will be treated with antibiotics prior to the planned 
treatment day (Day 9) by the study PI. The study PI may also determine the best route for antibiotic 
administration.  
Severe diarrhea (> 6 grade 3 -5 stools in 24 hours or > 800 g of grade 3 -5 stools in  24 hours).  
Fever (oral temperature ≥ 38.0°C present on at least two occasions, at least 20 minutes apart) with at 
least one associated symptom (nausea, vomiting, abdominal cramps, tenesmus, or gross blood in ≥ 2 
loose stools).  
A study physician determines  early treatment is warranted for other reasons.  
 
Any s ubjects meeting discharge criteria will be released with the remaining antibiotic treatment to be 
taken at home.  
9. Study  Evaluations  
9.1 Specimen preparation, handling, and shipping  
Research microbiology, i ncluding the preparation of live inoculum and culturing of stool specimens, will 
be carried out at Center for Vaccine Development (CVD) Microbiology Laboratory.  
No greater than 500 mL of blood will be collected per subject during any 8 -week period of the s tudy in 
keeping with FDA and Red Cross guidelines.  
Stool samples for fecal biomarkers (for example, fecal total protein, fecal calprotectin, fecal lipocalin, 
fecal myeloperoxidase, fecal neopterin, fecal lactoferrin, fecal cytokines, and/or fecal microbiom e) will 
Lumen Bioscience, Inc.  Confidential  Page 36 be placed into a sealed container with an ice pack in a cool bag. Samples will be transported to the CVD 
laboratory for processing, storage, and testing.  
Post challenge , at each non in unit  visit through Day 87 (Day 1 15 if there is any recrudescen ce) stool 
samples for Campylobacter  jejuni  culture and/or fecal biomarkers will be placed into a sealed container 
with an ice pack in a cool bag and brought to the clinic within 8 hours of production (per Laboratory 
Manual).  
9.2 Clinical laboratory evaluations  
Standard clinical laboratory tests for the purpose of inclusion and exclusion of potential subjects and as 
clinically indicated for safety monitoring will be carried out at Pharmaron Laboratories, a Clinical 
Laboratory Improvement Amendments ( CLIA )-certified laboratory . Quest will perform Campylobacter  
jejuni  blood cultures.  
The stool bacteriology performed post -inoculation will be carried out in the CVD Microbiology 
Laboratory , which is CLIA -certified . Until the start of antibiotics, up to tw o stool cultures per subject will 
be performed daily. Beginning 24 hours after the start of antibiotics, up to three  specimens per day will 
be cultured per subject . If the subject cannot provide a stool sample within the time window for each 
visit day,  then a rectal swab may be taken.  
9.3 Clinical evaluations  
The severity grading for the adverse events listed below is to ensure consistency with other bacterial 
enteric disease experimental infection stud ies. 
Clinical definitions  
Campylobacteriosis:  Clinical illness meeting at least one of the following patterns with documented C. 
jejuni infection occurring within 144 hours of challenge:  
Moderate to severe diarrhea (≥ 4 loose stools or ≥ 401 g of loose sto ols in 24 hours); or  
Fever (oral temperature ≥ 38.0°C , present on at least two occasions, at least 20 minutes apart) with 
at least one of the following symptoms of moderate severity: nausea, vomiting, abdominal cramps, 
tenesmus; or  
Fever (oral temperature ≥ 38.0°C present on at least two occasions, at least 20 minutes apart) with 
gross blood in ≥ 2 loose stools  
Infection:  Positive C. jejuni  stool culture in two stool cultures > 24 hours post -inoculation or a positive C. 
jejuni  stool culture > 24 hours post -inoculation with associated clinical symptoms meeting the 
campylob acteriosis endpoint definition.  
Grading system for stools:  
Grade 1: firm, formed (normal)  
Grade 2: soft, formed (normal)  
Grade 3: viscous opaque liquid or semi -liquid which assumes the shape of the container  
Grade 4: watery, non -viscous, opaque liquid which assumes the shape of the container  
Grade 5: clear or translucent, watery, or mucoid liquid which assumes the shape of the container  
 
Diarrhea:  
Lumen Bioscience, Inc.  Confidential  Page 37 One loose/liquid stool (grade 3 -5) of > 300 g within 144 h of Campylobacter  jejuni  challenge ;  
OR 
At least two loose/liquid stools totaling > 200 g during any 48 -hour period within 144 hours of 
challenge with Campylobacter  jejuni  
OR 
≥ 3 loose or liquid stools in a 24 -hour period regardless of volume.  
Diarrhea severity (determined within 144 hours of challenge): diarrhea severity is determined by 
frequency , within a 24 -hour period , and by total diarrhea (grade 3 -5 stools) volume during episode. The 
grade selected is the higher severity by either frequency or volume. Table 2 displays the grading scheme:  
Table 2: Severity grading scheme.  
Severity Grade  Parameter  
Mild  2-3 or more grad e 3-5 stools in a 48 -hour 
period totalling 200 -400 g or more or a single 
grade 3 -5 stool of 300 g in 24 hours  
Moderate  4-5 grade 3 -5 stools in 24 hours or 401 -800 g 
of grade 3 -5 stools for total episode  
Severe  > 6 grade 3 -5 stools in 24 hours or > 800 g  of 
grade 3 -5 stools for total episode  
 
Dysentery:  Gross blood observed in ≥ 2 stools Grade 3 -5 
Recrudescence of infection:  Positive stool culture for the C. jejuni strain used for inoculation occurring 
after a complete course of antibiotics, clinical improvement, and clearance of stool cultures (2 
specimens, a minimum of 12 hours apart), with or without symptoms of infection.  
Hypovolemia:  Confirmed (after 5 minutes) supine systolic blood pressure (BP) < 90 mmHg with 
associated symptoms or sign ificant lightheadedness on standing with a confirmed postural change in BP 
or pulse. Postural vital signs will be measured lying and 2 minutes after standing. A significant change 
will be any of the following: decrease in systolic BP or diastolic BP of > 2 0 mmHg; increase in pulse of > 
30 beats/min; or upon Principal Investigator discretion.  
Fever:  An oral temperature ≥ 38.0°C (100.4°F) present on at least two occasions 20 minutes or more 
apart.  
Arthralgia:  Persistent pain or stiffness in a joint without an y evidence of swelling or inflammation. If a 
subject does have arthralgia,  then a targeted history will be taken to determine whether there is an 
attributable cause for the pain, such as exercise.  
Arthritis:  Persistent pain or stiffness in a joint with evi dence of inflammation by physical exam.  
Reactive arthritis:  An arthritis that develops soon after an infection elsewhere in the body without a 
microorganism being isolated from a joint. Symptoms typically begin within 1 to 4 weeks after an 
infectious event . Reactive arthritis is generally monoarticular or oligoarticular. It is generally an 
asymmetric, additive arthritis, with new joints becoming involved over a period of days to 1 to 2 weeks. 
Lumen Bioscience, Inc.  Confidential  Page 38 The joints of the lower extremities are most commonly affected, including  knees, ankle, subtalar, 
metatarsophalangeal, and interphalangeal joints. The wrists and fingers may also be involved. 
Tendonitis and fasciitis, particularly involving the Achilles tendon and plantar fascia, are characteristic. 
Joints are painful a nd can be swollen. Morning stiffness is a prominent feature. Symptoms should last 
greater than one month. Involvement of the skin, eyes, and cardiovascular system are seen, but have 
not been reported with campylobacter -associated disease. If suspected, sub jects will be evaluated by a 
Board -certified rheumatologist. Procedures will be established prior to the study to ensure timely 
evaluation and management of any subject with possible post -infectious reactive arthritis. There is no 
specific diagnostic test.  HLA-B27 is present in in 30 -50% of those with reactive arthritis and is an 
exclusionary criterion for this study.  
Guillain -Barré syndrome (GBS):  The diagnosis of GBS requires progressive weakness of the arms and 
legs and areflexia. The diagnosis of GBS is  supported by symmetric and progressive symptoms, recovery 
beginning 2 to 4 weeks after progression ceases, mild or no sensory symptoms, cranial nerve 
involvement, autonomic dysfunction, absence of fever at the onset, elevated cerebrospinal fluid (CSF) 
protein with < 10 white cells, and typical electrodiagnostic features. If suspected, subjects will be 
evaluated by a Board -certified neurologist. Procedures will be established prior to the study to ensure 
timely evaluation and management of any subject with possible post -infectious GBS. The development 
of GBS will be reported as a SAE.  
9.4 Pharma cokinetics  
The serum levels of VHH will be evaluated on the following time schedule:  before the first dose; 2 ± 1 
hours after the first dose; Day 4, Day 7, Day 10, and Da y 24 .  
Anti -drug antibodies : Serum will be collected at baseline  and Day 24  for potential determin ation of 
the presence of anti -VHH antibodies. Anti -VHH antibody determinations will be performed if 
measurable systemic  absorption of VHH is demonstrated.  If anti -drug antibodies are confirmed, 
additional testing on the samples may be performed (e.g., titer and neu tralizing antibodies)  to further 
understand the process . 
Exploratory biomarkers : Biomarkers in the stool may be explored (e.g., fecal total protein, fecal 
calprotectin, fecal lipocalin, fecal myeloperoxidase, fecal neopterin, fecal lactoferrin, fecal cytok ines 
and/or fecal microbiome) as well systemic inflammatory responses (e.g., serum C -reactive protein). 
Serum, plasma, whole blood, and/or stool may be banked for future research evaluation.  
10. Investigational product  
10.1 Investigational product  
The investigational product , LMN -101 and placebo , will be supplied by Lumen Bioscience, Inc. (Seattle, 
Washington, USA). LMN -101 is VHH -derived binding protein designed  to bind and inhibit FlaA (a flagellin 
filament protein of C. jejuni ), delivered in whole, s pray -dried, spirulina biomass.  
The LMN -101 drug substance is manufactured using a stable  spirulina  cell line that was engineered to 
constitutively express the VHH protein aa682 under cGMP using recombinant DNA processes and 
controls. The cells are cultured  using chemically defined, animal product -free basal medium under 
photoautotrophic growth conditions, utilizing bicarbonate and CO 2 as the carbon source. After 
Lumen Bioscience, Inc.  Confidential  Page 39 harvesting and rinsing with a dilute solution of trehalose, cells are spray dried to produce dru g 
substance. The drug substance is fully tested against established  and validated  specifications prior to 
release for further processing and use in clinical studies. Spirulina drug substance is produced in the 
identical manner except for lacking the VHH pr otein.  
LMN -101 drug product is manufactured at Lumen’s cGMP manufacturing facility in Seattle, Washington 
USA. The drug substance is provided in pre -formulated capsules. The LMN -101 drug product is tested for 
potency and purity defined by established and v alidated specifications. Lumen’s cell banking protocols 
are designed to comply with ICH guideline Q5D for microbial cells. Spirulina cells expressing aa682 (or 
wild -type spirulina without aa682 ) are cultured indoors in photobioreactors enclosing disposable  
polyethylene bags. Spirulina’s preferred growth regimen (high pH, high salinity, high temperature, and 
absence of any exogenous energy source other than light) suppresses the growth of contaminants and 
thus safely allows high production rates under sanita ry conditions. The collected biomass is rinsed by a 
dilute solution of trehalose and collected by filtration. The resulting paste is spray dried to produce a 
fine powder. The material is dried to less than 6% moisture and is stored at room temperature in a  
sealed container. For this study, doses of LMN -101 will be delivered as a spray -dried, trehalose -
stabilized spirulina powder with or without VHH in size 00 white, opaque, capsules without additional 
excipients. Doses of placebo will be delivered as identi cal-appearing cornstarch NF with coloring in size 
00, white, opaque, capsules. No capsules contain any materials of human or animal origin.  
10.2 Dosing regimen of investigational product   
Subjects will receive LMN -101, 3000 mg (taken as six LMN -101 500 -mg caps ules each containing 500 mg 
of spirulina -VHH, strain SP1182) orally three times daily for 14 days (n= 21 subjects ), or identical -appearing 
placebo (n= 21 subjects ). 
10.3 Dispensing of investigational product  
The investigational pharmacy will dispense LMN -101 and /or placebo according to the Pharmacy Manual . 
All will be identical in appearance and dispensed according to the subject’s treatment number . 
Dispensing packets, with appropriate labels will be generated  for each individual subject. The process for 
preparing LMN -101 and placebo, as well as blinding and packaging, is detailed  in Pharma cy Manual . 
10.4 Dosage form of investigational product  
LMN -101 ingredients are spray -dried spirulina biomass ( with  the aa682 pro tein) and trehalose.  Placebo 
is identical -appearing , starch -based  powder.  LMN -101 and placebo doses  are packaged in size  00, white, 
opaque capsules (Capsugel, Morristown, NJ, US) . No capsules contain any materials of human or animal 
origin. While in unit, the IP doses will be co -administered with 50 mL of sodium bicarbonate solution.  
10.5 Route of administration of investigational product  
LMN -101 and placebo must be administered orally and may be taken with fluids or food.  While in unit, 
doses will be co -administered with 50 mL of bicarbonate buffer. B icarbonate buffer  consists of  2 g USP -
grade sodium bicarbonate  in a total of 150 mL water . Subjects will drink 50 mL of buffer, followed 
approximately 1 minute later by IP. The IP may be taken with additional water.   Bicarbonate buffer  will 
be provided for subjects  for doses post discharge . Subjects will be encouraged to drink 50 mL of buffer, 
followed approximately 1 minute later by IP. 
Lumen Bioscience, Inc.  Confidential  Page 40 10.6 Timing of dosing of investigational product  
Capsules are to be self -admini stered by the subject three times daily. The subject will be provided a diary 
by the research clinic to record study drug administration, date, and time . 
10.7 Packaging and labeling of investigational product  
Investigational product will be provided in individu al dose packets, labeled appr opriately . While not in 
unit, subjects will be provided the requisite number of doses of study drug supply until their next 
scheduled study visit as detailed in the Pharmacy Manual. Product labeling states:  
CAM02 Investigational Drug  LMN -101 500-mg capsules  – ACTIVE  or Placebo , 6 capsules  per 
container  
For oral use only,  Take  as directed   
Lot No:  LMN -101-500mg  XXXXXXX (blinding code)  
Expiration  Date:  MONTH  YEAR  Store  at 15-25° C (59-77° F)  
Manufactured  by Lumen  Bioscience,  Inc.  
1441  North  34th  Street,  Suite  300 Seattle,  WA 98103  USA  
Tel: +1 (206) 899 -1904   
Caution —New Drug --Limited by United States law to investigational use  only   
Keep out of reach of children   
10.8 Storage and handling  of investigational product  
All Investigational Products will be kept in a locked area with limited access.  Capsules containing 
investigational product  should be stored at room temperature, 59 -77°F (15-25°C) and protected from 
moisture, light, and extreme heat during storage. Capsules contain no preservatives. Any damaged or 
partially used capsules should be returned to the investigational pharmacy and discarded using 
appropriate drug disposal procedures and documented.  
Subjects should be instructed to main tain investigational product away from excessive heat (104°F 
[40°C]) and moisture.  
Only subjects enrolled in the study may receive the investigational product , and the challenge strain, in 
accordance with all applicable regulatory requirements.  Upon the co mpletion of the study, this material 
will be subjected to final inspection and reconciliation. At that time, all unused, partially used, and fully 
used (empty) container (s) along with a  packing slip must be destroyed as per Pharmacy Manual. 
Documentation o f destruction will be retained by the investigational pharmacy with the study files.  
10.9 C. jejuni challenge strain CG8421  
A human challenge model for studies investigating C. jejuni has already been established.  It uses the 
strain C. jejuni  CG8421. In addition to mitigating the risk of GBS  by lacking  ganglioside mimicry, the 
CG8421  strain  model  has an acceptable safety profile,  with  a consistently  high  attack rate and  robust 
immune responses when using a low concentration of inoculum (5 x 105 CFUs). Whe n tested previously, 
clinical disease after CG8421  infection  consisted of moderate -to-large volume diarrhea with symptoms 
of headache, myalgia,  and abdominal  cramping.  Fever  occurred  in 39-53% of subjects depending on 
study and cohort . There  were  no signif icant clinical differences between  individual s who received 106 
Lumen Bioscience, Inc.  Confidential  Page 41 and 105 CFUs of C. jejuni , although subjects who received  the lower  dose  had a slightly  longer  incubation  
period and a lower total  volume  of loose  stools  (Tribble  et al.  2009) . There were no serious  adverse  
events  related  to CG8421 and no hypotension/sho ck or post -infectious sequelae.  After initiation of 
antibiotics in subjects, symptoms resolved, and stool cultures cleared rapidly. However, after receiving 
ciprofloxacin monotherapy, 4% of subjects  develop ed recrudescent infection, despite prior resolutio n of 
symptoms and clearance of CG8421 from stool cultures. Due to this, the antibiotic regimen was 
increas ed to combination azithromycin and ciprofloxacin for 5 days  based on recommendations of an 
independent Expert Advisory Committee . Despite this, in the  most recent study the recrudescence rate 
was 18%  (Rimmer  et al.  2018) . Shedding was eliminated with further dual antibiotic therapy 
(ciprofloxacin and azithromycin  for 10 days ). 
The challenge model that will be used for this study will use 5 x 105 CFU of C. jejuni CG8421.  
10.10  Preparation of challenge strain  
The C. jejuni  challenge strain underwent cGMP production at Char les River Laboratories (358 Technology 
Drive, Malvern, PA 19355, 610 -640-4550) in October 2006. A Master Cell Bank (MCB) was prepared from 
the research seed upon release of the strain. The cGMP cell bank was released based on the criteria 
outlined in Table  4.  
Table 4: Release Criteria for C. jejuni cGMP MCB  
Parameter  Methodology  Specification  
Viability  Plating on Mueller -Hinton agar, incubation in a jar with 
campylobacter -specific gas mix  at 37°C for 48 h. ≥ 106 CFU/vial  
Purity  Plating on the appropriate selective agar  to include sheep blood 
and Sabouraud -Dextrose agar . Incubation of plates under aerobic 
conditions, 37 °C 18-24 h. No contaminating 
organisms on agar 
plates  
Identity  16S RNA analysis and C. jejuni -specific PCR  C. jejuni  
10.11  Packaging and labeling of challenge strain  
The CG8421 challenge strain is stored as 1-mL aliquots in 2-mL cryostorage tubes (1 mL per tube) held at -80°C 
± 10°C in the WRAIR Pilot Bioproduction Facility ( PBF). The cryotubes are  labeled  as shown  in Figure 2.  
Campylobacter jejuni strain CG-99-8421 CRL # 498006 -1 
Mfg. Date 07 Oct 06 Vial # xxx of 210 Store at -70 + 10 °C 
Prepared by Charles River Laboratories Malvern PA  
Figure 2: Cryotube labels  
10.12  Storage and transportation  of challenge strain  
The vials will be transferred on dry ice from the WRAIR Pilot Bioproduction Facility to CVD Microbiology 
Laboratory , logged in, and stored at -80°C ± 10 °C in a locked and temperature -monitored ultra -low 
temperature  freezer.  Any use of these vials will be done under the supervision of qualified and trained 
CVD Microbiology Laboratory  personnel and tracked in  a strain accountability log. Any vials remaining at  
the end of the  study will  be returned  to NMRC or disposed by autoclaving.  
Lumen Bioscience, Inc.  Confidential  Page 42 10.13  Prepa ration, administration, and inoculum size of challenge strain  
The preparation of the challenge strain is outlined in “ED_CampyRif01_SSP402” version 1.0 November 3, 
2014, “Site -Specific Procedure (SSP)”. An appropriate number of master seed vials that have been stored 
at -80°C ± 10 °C in Mueller -Hinton broth with 15% glycerol will be  thawed  at room temperature.  One 
hundred microliters  of the master  seed  lot will be spread  onto  an appropriate  number  of Mueller -Hinton  
agar  plates for confluent growth and  incubated  overnight  (21 ± 1 hour)  at 40 ± 2°C under  microaerobic 
conditions  achieved  using  a BBL CampyPak Plus  (BD).  After overnight growth,  C. jejuni  identity will be 
confirmed by purity testing, morphology, g ram stain, oxidase testing , catalase testing, and confirmation  
of darting  motility. Bacterial biomass will be harvested by suspension  in sterile  PBS (0.01M sodium  
phosphate,  0.138M  sodium  chloride,  0.0027M  potassium  chloride,  pH 7.4) and adjusted to the 
appropriate  OD600  to achieve  the target  infectious  dose.  Challenge inoculum will be verified by 
enumeration of viable counts on  Mueller -Hinton  agar  and Campy CVA in triplicate  on the sample both 
the pre - and post -dosing (the mean of the pre - and post -dose CFU will be used  for the estimated 
inocu lum size). Purity will be determined by plating the  challenge  inoculum  on sheep blood agar and 
incubating  2 plates  at 37 °C and 2 plates at 42 °C for 24 -48 hours under aerobic conditions.   
C. jejuni  CG8421 will be administered with bicarbonate buffer (2 g in  a total of 150 mL). Study 
participants  are fasted for at least 90 minutes before and 90 minutes after challenge.  At challenge, 
study participants  will drink 120 mL of buffer, followed approximately 1 minute later by 30 mL of buffer 
containing CG8421. The  CG8421 will be added to the bicarbonate immediately before dosing.  
10.14  Antibiotics  
Ciprofloxacin, 500 -mg tabs, and azithromycin, 500 -mg tabs, will be supplied through the investigational 
pharmacy for oral administration for 5 days (daily for azithromycin, twi ce daily for ciprofloxacin). If the 
study physician determines that alternative or IV antibiotics are required , these will be supplied through 
the pharmacy. This five -day course of antibiotic therapy was recommended by an Expert Advisory 
Committee.  
10.15  Assess ment of subject compliance with investigational products  
A member of the study team will witness the ingestion of the first dose of investigational product  (IP). 
The subject will be given a diary to take home to document subsequent doses of the IP. While in unit , 
the subject will be administered the IP, challenge, and antibiotics under direct observation. If subject is 
to complete the antibiotic course at home, then the subject will be questioned regarding compliance at 
the next study visit and diary revie wed.  
10.16  Missed doses of LMN -101 or placebo  
Any missed doses of IP during the non in unit portion will be documented and the subject will be asked 
to bring in the medicine container and untaken pills. The returned doses will be documented in the 
subject chart,  the bottles will be tagged to be returned to the investigational pharmacy, and 
documentation maintained in the study binder for drug accountability.  
Any subject missing the two doses of IP immediately prior to challenge will not be eligible for challenge.  
Missed dose(s) will be documented along with the reason for the missed dose.  
Lumen Bioscience, Inc.  Confidential  Page 43 If a dose is refused due to illness during the study, the missed dose will be clearly documented, and the 
extra dose(s) will be returned to the pharmacy with tracking at the end  of the in-unit phase of the study. 
If a subject vomits within one hour of the dose, attempts will be made to re -dose the subject. This will 
be clearly documented in the subject’s records.  
If a subject refuses a dose not due to illness, staff will notify the PI or designee, and a reason will be 
documented.  
11. Safety Management  
11.1 Adverse events  
The Principal Investigator is responsible for documentation of AEs according to the detailed guidelines 
below. Subjects will be instructed to contact the Principal Investigator or designee immediately should 
they manifest any signs or symptoms they perceiv e as serious during the study period as well as prompt 
notification for any new onset of gastrointestinal symptoms irrespective of severity (through Day 59). 
Approximately six months after receiving the C. jejuni challenge dose, the subjects will be contac ted by 
phone to document any intervening medically significant new chronic illnesses or serious adverse  
events. These data will be documented in the subject’s source documents and CRFs , then summarized in 
an appendix to the final clinical study report.  
11.2 Definition s 
An AE is any untoward medical occurrence or change in a clinical trial subject having received a biologic 
or medicinal product (trial related) and does not need to have a causal relationship with this treatment. 
This includes any noxious, patholog ical, or unintended change in anatomical, physiologic, or metabolic 
functions as indicated by physical signs, symptoms, and/or clinically significant laboratory abnormalities. 
This may occur in any phase of the clinical study whether  associated with the st udy product and 
whether  considered product related. This includes an exacerbation or worsening of pre -existing 
conditions or events; intercurrent illnesses, injuries, or vaccine or drug interaction; or worsening of 
abnormal clinical laboratory values. Anti cipated day -to-day fluctuations of pre -existing conditions that 
do not represent a clinically significant exacerbation need not be considered AEs. Discrete episodes or 
worsening of chronic conditions occurring during a study period should be reported as AE s to assess 
changes in frequency or severity. Stable, pre -existing conditions and/or elective procedures are not AEs. 
AEs will be documented in terms of signs and symptoms observed by the Principal Investigator or 
reported by the subjects at each study enc ounter, with a medical diagnosis stated. Pre -existing 
conditions or signs and/or symptoms (including any which are not recognized at study entry but are 
recognized during the study period) present in a subject prior to the start of the study should be 
reco rded in the Medical History form within the subject’s CRF. AEs that occur after informed consent is 
obtained, but prior to test article receipt, will be documented in the Medical History form within the 
subject's CRF as instructed by the clinical research monitor.  
A serious adverse event (SAE) is any untoward medical occurrence or effect at any dose that results in:  
• Death  
• Is immediately life threatening  
Lumen Bioscience, Inc.  Confidential  Page 44 • Results in persistent or significant disability/incapacity  
• Requires inpatient hospitalization or prolonga tion of existing hospitalization  
• Results in congenital anomaly/birth defect in the offspring of a study subject  
• Is an important medical event that may jeopardize the individual  or may require intervention to 
prevent one of the other outcomes listed above.  
Although not considered SAEs, cancers should be reported in the same way as SAEs.  
Pertinent definitions include:  
Life threatening:  
An AE is life threatening if the subject was at risk of death at the time of the event; it does not refer to 
an event that h ypothetically might have caused death if it were more severe.  
Disabling/incapacitating:  
An AE is incapacitating or disabling if it results in a substantial disruption of the subject’s ability to carry 
out normal life functions. This definition is not inten ded to include experiences of relatively minor 
medical significance such as headache, nausea, vomiting, diarrhea, influenza, injection site reactions and 
accidental trauma (e.g., sprained ankle).  
Although not an SAE, the FDA has requested that all instance s of recrudescence be reported analogous 
to SAE reporting.  
Hospitalization:  
In general, hospitalization signifies that the subject has been detained (usually involving at least an 
overnight stay) at the hospital or emergency department for treatment that w ould not have been 
appropriate in the physician's office or outpatient setting. Hospitalization for either cosmetic surgery or 
elective surgery related to a pre -existing condition which did not increase in severity or frequency 
following initiation of the study, or for routine clinical procedures that are not the result of an adverse 
event, need not be considered as AEs and are therefore not SAEs. Since this is an in-unit study, the 
planned in unit  period is not to be recorded as a SAE. An extension of the planned hospitalization due to 
a potentially life -threatening health condition will be reported as a SAE. An extension of the 
hospitalization a day or two to fulfill discharge criteria is not considered as a SAE.  
Routine Clinical Procedure:  
A procedure whi ch takes place during the study and does not interfere with the test article 
administration or any of the ongoing protocol specific procedures.  
If any adverse event is reported during an elective procedure, that occurrence must be reported as an 
adverse ev ent, either ‘serious’ or ‘non -serious’ according to the usual criteria. When in doubt as to 
whether ‘hospitalization’ occurred or was necessary, the AE should be considered serious.  
11.3 Assessment of severity  
Severity of the following adverse events (grades 0 -4) should be assessed as defined in Table 5 below to 
ensure consistency with previous experimental infection studies with other enteric pathogens. Adverse 
Lumen Bioscience, Inc.  Confidential  Page 45 Events not represented in the below criteria will be coded according to Common Terminology Criteria 
for Adverse Events (CTCEA), Version 5.0.  
Table 5: Adverse Event definitions and parameters for in unit  setting  
Adverse Event   
 
 Parameter  
Diarrhea   1 2-3 or more grade 3 -5 stools in a 48 -hour  period totalling 200 -400 
g or more or a single grade 3 -5 stool of 300 g in 24 hours  
2 4-5 grade 3 -5 stools in 24 hours or 401 -800 g of  grade 3 -5 stools 
for total episode  
3 > 6 grade 3 -5 stools in 24 hours or > 800 g  of grade 3 -5 stools for 
total episode  
4 Life-threatening  
Body Temperature  1 100.4 -101.1°F (38.0 -38.4°C)  
2 101.2 -102.0°F (38.5 -38.9°C)  
3 102.1 -104.9°F (39.0 -40.5°C)  
4 Life-threatening hyperthermia  
Vomiting  1 One episode within any 24 -hour period  
2 Two episodes within any 24-hour period  
3 More than two episodes within any 24 -hour  period  
4 Life-threatening consequence of emesis  
1 = mild; 2 = moderate; 3 = severe; 4 = life -threatening  
 
11.4 Assessment of causality  
Every effort should be made to explain AEs and assess causal relationships, if any, to administration of 
the IP, Campylobacter  jejuni  challenge,  treatment antibiotics , or other study procedures . AEs occurring 
on study days prior to receipt of the challenge inoculum will be assessed as having no relationship with 
the challenge strain. AEs occurring after  receipt of the challenge will be assessed as to their relationship 
with the IP, Campylobacter  jejuni  challenge strain , treatment antibiotics or  other study procedures , if 
applicable. The degree of certainty with which an AE can be attributed to these products (or alternative 
causes, e.g., natural history  of the underlying diseases, concomitant therapy, etc.) will be determined by 
how well the event  can be understood in terms  of one or more of the  following:  
• Reaction of similar nature having previously been observed with Campylobacte r jejuni  challenge 
strains or antibiotic administration  
• Published literature accounts supporting causality  
• Temporal relationship with administration  
 
The Principal Investigator  will separately assess causality of all AEs as either ‘probably related’, ‘possibly 
related’, or ‘unrelated’ to the IP, Campylobacter  jejuni  challenge strain, treatment antibiotics, and other  
Lumen Bioscience, Inc.  Confidential  Page 46 study procedures. Non-serious and serious adverse events will be evaluated as two distinct types of  
events given their different medical nature. If an  event meets the criteria for a serious adverse event it 
will be examined by the Principal Investiga tor to the extent possible to determine ALL contributing 
factors applicable to the event.  
Other possible contributors  include:  
• Underlying disease  
• Other medication  
• Protocol -required procedure  
• Other cause (specify)  
 
“Probably related ” to IP is defined as evidence to suggest a causal relationship with IP, and the influence 
of other factors is unlikely. The event occurs within a reasonable time after administration of the study 
drug, is unlikely to be attributed to other drugs or partici pant’s underlying clinical condition and follows a 
clinically reasonable response on withdrawal of the study drug. Withdrawal and re -challenge data are not 
required to fulfill this definition.  
“Possibly related ” to IP is defined as some evidence to sugges t a causal relationship with IP, for example, 
the event occurred within a reasonable time after administration of the study drug. Other factors may 
have contributed to the event, for example, other drugs or the participant’s underlying clinical condition.  
“Unrelated ” to IP is defined as an event which has a temporal relationship to study drug that makes a 
causal relationship improbable, for example, the event did not occur within a reasonable time after 
administration of the study drug and in which other d rugs or participant’s underlying clinical condition 
provides plausible explanation.  
11.5 Anticipated adverse events  
This study is evaluating a challenge with live Campylobacter  jejuni  bacteria, and therefore all the 
symptoms of Campylobacter  jejuni  infection a re expected with severity grades ranging from 1 -3. Serious 
adverse events and Grade 4 adverse events related to  campylobacteriosis will be considered unexpected 
for the purposes of IND safety  reporting.  The most common effects of Campylobacter  jejuni  infec tion 
are moderate to severe diarrhea , which may lead to dehydration, electrolyte abnormalities and the 
need for oral or intravenous rehydration, abdominal cramping, and fever. Nausea with or without 
vomiting, chills, gross blood in stools, loss of appetite , headache, muscle aches, and bloating may also 
occur. Recrudescent events have been documented in up to 4 -18% of previous subjects receiving this 
dose.  
Adverse events of special interest are not expected due to their low likelihood of occurrence, but the y 
will be monitored. These include Guillain -Barre syndrome, neurodegenerative changes, arthritis, 
symptomatic uveitis, and myocarditis/pericarditis. GBS is thought to not be possible following challenge 
with the challenge strain due to the absence of the portion of the Campylobacter  jejuni  that cross reacts 
with neurologic tissue.  
Fluoroquinolones, including ciprofloxacin, are associated with an increased risk of tendinitis a nd tendon 
rupture in all ages. The risk of developing fluoroquinolone -associated tendinitis and tendon rupture is 
Lumen Bioscience, Inc.  Confidential  Page 47 further increased in older individual s usually over 60 years of age, in individual s taking corticosteroid 
drugs, and in individual s with kidne y, heart, or lung transplants, all of whom are excluded from this 
study.  
11.6 Out of unit adverse events  
Potential symptoms associated with the IP and study participation will be solicited from subjects using a 
Diary Card . 
Additionally, subjects will be asked daily about number of stools and if abnormal. If stool is reported as 
abnormal the clinic staff will then ask the subject questions to determine the grade of the stool and 
assess for diarrhea.  
• Hematology will be assessed about 7 days after starting the IP. 
• Chemistry will be assessed about 7 days after starting the IP.  
11.7 In unit participant  surveillance  
Subjects will continue to receive the IP during the in-unit phase of the study, however, once the 
challenge is given, the  solicited  adverse events experienc ed will be attributed to the challenge.  
Expected symptoms of campylobacteriosis will be specifically solicited daily during the in-unit period.  
“Specific solicited adverse events” are defined as  
• diarrhea,  
• fever,  
• nausea,  
• vomiting,  
• abdominal pain,  
• abdominal cramping,  
• tenesmus,  
• mucoid or bloody stools,  
• constipation,  
• headache,  
• lightheadedness,  
• fatigue,  
• lack of appetite,  
• muscle aches,  
• chills , 
• joint pains  
 
Symptoms that will be assessed objectively include:  
• Diarrhea  
• Fever  
• Dysentery (confirmed by hemoccult testing)  
Open -ended questions will also be used to capture any other symptoms during the study period. All AEs 
should be recorded on the appropriate AE form of the subject’s CRF and recorded irrespective of 
severity or whe ther or not they are considered related to the IP or challenge inoculum. AEs occurring 
Lumen Bioscience, Inc.  Confidential  Page 48 after receipt of the challenge (Day 3) will be assessed as to their relationship with the IP, the challenge 
strain, and the treatment antibiotics (if treatment has start ed). 
11.8 Out of unit  surveillance  
11.8.1  Discharge to Day  59 
Subjects will continue taking their assigned IP through the third dose  on Day 14. Assessment of specific 
solicited AEs will continue through Day 24. Assessment of AEs will continue through Day 59. Subjects will 
have memory aids or diaries to help them capture adverse events  through Day 24 .  
11.8.2  Day 59 to Day 190  
Additionally, subjects wil l be educated to telephone the investigative site if they experience any 
symptoms of diarrhea (3 loose stools/24 hours) or fever ≥ 38°C (100.4°F) with any associated severe 
symptoms (nausea, abdominal cramps, vomiting, myalgia, headache, arthralgia, or gro ss blood in their 
stool). Clinical staff will solicit at each visit any clinically apparent signs or symptoms of SAEs or AESIs  
(Guillain -Barre syndrome (GBS), neurodegenerative changes, arthritis, uveitis, and 
myocarditis/pericarditis).  
11.9 Recording adverse e vents  
A study investigator will evaluate all AEs either observed by the Principal Investigator or one of his/her 
clinical collaborators or reported by subjects spontaneously or in response to a direct question. Specific 
solicited adverse events (defined as  diarrhea, fever, nausea, vomiting, abdominal pain, abdominal 
cramping, tenesmus, mucoid or bloody stools, constipation, headache, lightheadedness, fatigue, lack of 
appetite, muscle aches, chills, and joint pains ) will be recorded through Day 24. The AE re cording period 
is from Day 1 through Day 59. SAEs and AESIs will be collected through Day 190. The nature of each 
event, date of onset, outcome, severity, and relationship to the challenge strain and/or antibiotic should 
be established. Details of any symp tomatic/corrective treatment should be recorded on the appropriate 
page of the eCRF. Subjects should be asked non -leading questions initially when soliciting AEs, followed 
by more direct questions as necessary. AEs already documented in the eCRF, i.e., at a previous 
assessment, should be reviewed at subsequent follow -up assessments and updated as necessary. If an 
AE changes significantly in frequency or intensity during a study period, a new record of the event will 
be started. Each solicited symptom/sign w ill be recorded separately as an AE. In some instances, the PI 
may classify some clinical syndromes as AE, rather than the individual signs and/or symptoms.  
11.10  Follow -up of adverse events and assessment of outcome  
Outcome should be assessed as:  
• Resolved  
• Resolved with sequelae  
• Severity change  
• Ongoing at study conclusion  
• Died  
• Lost to follow up  
Lumen Bioscience, Inc.  Confidential  Page 49 Investigators should follow -up all AEs until Day 59 this may include repeat safety laboratory analysis. At 
the clinical visits on Day 87, and Day 115, and th e telephone call on Day 190, the Principal Investigator 
will follow  the subject as outlined assess for the onset of SAEs and AESIs.  
11.11  Reporting serious adverse events  
All SAEs must be reported immediately  to the sponsor  by the Principal Investigator, whether or not 
regarded as possibly attributable to the test articles , antibiotic s, Campylobacter  jejuni  challenge strain, 
or other study procedures . Serious adverse events and Grade 4 adverse events related to 
campylobacter iosis will be considered unexpected for the purposes of IND safet y reporting.  Any 
unexpected fatal or life -threatening suspected adverse reaction (s) will be reported to the FDA by the 
Sponsor. SAE reports will be provided to the Sponsor, Medical Monitor, and the IRB (IntegReview IRB); 
contact information is provided on cover pages. The Principal Investigator must report SAEs within 24 
hours of becoming aware of the event by telephone or e -mail (if appropriate) to the study contacts as 
described in  the protocol. This initial notification should include minimal, but sufficient information to 
permit identification of the reporter, the subject, the test articles, SAEs, and date of onset. The Principal 
Investigator should not wait for additional informa tion to fully document the event before notifying. The 
report is then to be followed by submission of a completed SAE Report Form provided by the Sponsor as 
soon as possible but not more than 3 working days past the initial report, detailing relevant aspec ts of 
the SAE in question. All Principal Investigator actions and event outcomes must also be reported 
immediately.  
Related and unanticipated SAEs or related severe (grade 3 or greater) unanticipated AEs will be sent to 
the IRBs and Sponsor within 24 hours . SAE Report Forms are to be used for documentation of these 
various aspects regarding the event. Hospital records and autopsy reports should be obtained if 
applicable.  
11.11.1  Sponsor notification by Principal Investigator  
The Principal Investigator must report a ll SAEs immediately (within 24 hours of identification), whether 
or not the event is considered related to the study product, and provide to the Sponsor the following 
information via email (preferred) or telephone:  
• Protocol IND number, investigational prod uct, Principal Investigator name, and contact number  
• Subject identification number  and product blinding code from IP label  
• Serious adverse event, onset date, date of investigational product administration, severity, 
relationship  to the test articles, antib iotics, Campylobacter  jejuni  challenge strain, or other study 
procedures , and subject’s current status  
AND  
Email the following documents to Medical Monitor, Lumen Bioscience:  
• Cover sheet  
• Adverse Event Case Report Form  
• Supplemental Serious Adverse Event Report Form  
• Concomitant Medication Case Report Form or a list of concomitant medications  
Lumen Bioscience, Inc.  Confidential  Page 50 • Medical record progress notes including pertinent laboratory/diagnostic test results  
The Principal Investigator will assess all SAEs as being either related or u nrelated to the administered 
product.  The Sponsor contact is noted on the cover page of this protocol.  
The Principal Investigator must report these additional immediately reportable events within 24 hours 
of identification to the Sponsor:  
• Any withdrawal o f consent during the study  
• Pregnancy or intent to become pregnant  
• A protocol deviation that jeopardizes the safety of a subject or scientific integrity of the study  
11.11.2  Institutional Review Boards  
Unanticipated problems involving risk to subjects or others, se rious adverse events related to 
participation in the study and all subject deaths should be promptly reported by phone or email to the 
IntegReview IRB. A written report will follow the initial notification.  
Investigators are required to forward safety info rmation provided by the Sponsor’s representative to the 
IRB. All SAEs will be reported to the IRBs within 24 hours of the Principal Investigator becoming aware of 
the event.  
Table 6: Contact Information  
IRB Telephone/Fax  Email  Address  
IntegReview IRB  (512) 326 -3001  
(512) 697 -0085  vgovea@integreview.com  3815 S. Capital of Texas Hwy  
Suite 320  
Austin, TX 78704  
 
11.11.3  FDA notification by Sponsor  
The Sponsor will be responsible for notifying the FDA of any unexpected fatal or life-threatening 
suspected adverse reaction s as soon as possible, but in no case later than 7 calendar days after the 
Sponsor’s initial receipt of the information. In addition, the Sponsor must notify the FDA and all 
participating investigators in an IND s afety report of potential serious risks, from clinical trials or any 
other source, as soon as possible, but in no case later than 15 calendar days after the Sponsor 
determines that the information qualifies for reporting.  
In each IND safety report, the Sp onsor must identify all IND safety reports previously submitted to FDA 
concerning a similar suspected adverse reaction and  must analyze the significance of the suspected 
adverse reaction in light of previous, similar reports or any other relevant informati on. The Sponsor 
must report any suspected adverse reaction that is both serious and unexpected. The Sponsor must 
report an adverse event as a suspected adverse reaction only if there is evidence to suggest a causal 
relationship between a drug (including antibiotics) and the adverse event, such as: (A) A single 
occurrence of an event that is uncommon and known to be strongly associated with drug exposure (e.g., 
angioedema, hepatic injury, Stevens -Johnson Syndrome); (B) One or more occurrences of  an event that 
is not commonly associated with drug exposure, but is otherwise uncommon in the population exposed 
to the drug (e.g., tendon rupture); (C) An aggregate analysis of specific events observed in a clinical trial 
(such as known consequences of t he underlying disease or condition under investigation or other events 
Lumen Bioscience, Inc.  Confidential  Page 51 that commonly occur in the study population independent of drug therapy) that indicates those events 
occur more frequently in a drug  treatment group than in a concurrent or historical  ̮control group.  
11.12  Follow -up of serious adverse events  
All SAEs must be documented and followed until the event either resolves, subsides, stabilizes, 
disappears, or is otherwise explained, or the subject is lost to follow -up, but not longer than 6 months 
after the last receipt of test article. All follow -up activities have to be reported, if necessary, on one or 
more consecutive SAE report forms, in a timely manner. All fields with additional or changed 
information must be completed and the report form should be forwarded to the study contact for 
reporting SAEs as soon as possible, but not more than 7 calendar days after receipt of the new 
information. Clinically significant laboratory abnormalities will be followed up until they have returned 
to normal or unti l stable. Reports relative to the subsequent course of an AE noted for any subject must 
be submitted to the Sponsor. The outcome of SAEs should be assessed in the same manner as all AEs.  
11.13  Treatment of adverse events  
Treatment of an AE is determined by the P rincipal Investigator and according to the best treatment 
currently available. The applied measures should be recorded in the CRF for the subject.  
11.14  Discontinuation/withdrawal from study  
Based on prior experience with C. jejuni  challenge studies, it is expec ted that some subjects will have 
severe (grade 3) AEs (such as severe diarrhea) but not grade 4.  
AEs which will prompt stopping the investigational product administration for all subjects and review 
include:  
• Any individual experiencing any SAE  considered a t least possibly related to the investigational 
products;  or 
• If two or more subjects experience the same or similar unanticipated adverse event that is 
Grade 3 or higher ; or 
• If any subject experiences an AESI (GBS, uveitis, arthritis, or myocarditis/perica rditis); or  
• If the accumulation of SAEs and/or severe AEs collectively raises a safety concern in the opinion 
of the PI, Medical Monitor, or Sponsor.  
This does not include two or more subjects experiencing anticipated severe (grade 3) AEs (such as 
severe diarrhea, ab dominal cramps, fever, or other symptoms included in the clinical definition of 
campylobacteriosis) specifically during the in-unit period  (but specifically DOES include all grade 3 AEs 
that occur post clinical research center discharge) . 
The decision to restart will be  made by consensus of a review committee  comprised of the Independent 
Medical Monitor , the sponsor’s medical expert , and the Principal Investigator.   The decision to stop the 
study will be communicated to the IRB and, similarl y, the decision to re -start a study  will also be 
communicated to the IRB.   
AEs which will prompt a n Independent Medical  Monitor review include:  
• If one or more subjects experiences a moderate -to-severe symptomatic recrudescence.  
Lumen Bioscience, Inc.  Confidential  Page 52 Administration of the inves tigational  product will be discontinued for any subject  that develops : 
• A serious adverse event; or  
• An adverse event that is Grade 3 or higher and considered at least possibly related to the 
investigational product (excluding in -unit events related to campylobacteriosis as described in 
the protocol) ; or 
• The Principal Investigator deems that stopping the investigational product administration is in 
the best interest of the subject.  
 
Additional reasons for individual subject withdrawal include:  
• The subjec t does not wish to continue with the study; or  
• The subject is lost to follow -up. 
 
Withdrawal/stopping of the trial due to these last two points, if not AE related, does not need to be 
reported other than as part of routine annual reporting to the FDA and I RBs.  
11.15  Right to terminate the study  
Both Lumen Bioscience and the Principal Investigator have the right to terminate this study at any time, 
and to arrange an appropriately agreed upon schedule for termination, if necessary. This information 
will be provided  to each subject or legally authorized representative during the informed consent 
process.  
12. Statistical considerations  
12.1 Statistical hypothesis  
The primary endpoint of the study is to compare the frequency of solicited and unsolicited adverse 
events in subjec ts that received LMN -101 compared to placebo . Event rates will be reported for the two 
treatment arms, but no statistical hypothesis tests will be performed for the primary endpoint  due to 
the uncertain frequency of AEs in the placebo arm and the anticipat ed low rate of AEs in the treatment 
arm.  
The secondary endpoint is t o compare LMN -101 to placebo in the proportion of subjects with 
campylobacteriosis after challenge with Campylobacter jejuni  strain CG8421 . The null hypothesis, that 
the risk ratio for campylobacteriosis  (LMN -101 / placebo) is one, will be tested against the 2 -sided 
alternative at the 0.10 level of significance.  
12.2 Sample size considerations  
The sample size for this study was selected to be large enough so that an adverse event that occurs with 
5-10% frequency with LMN -101 administration in the context of Campylobacter  jejuni  exposure is likely 
to be observed in the study. However, practical a nd ethical considerations for this human challenge 
study were also important in limiting the size of the study.  With 21 subjects receiving LMN -101, there is 
a 66% probability that an adverse event expected to occur in 5% of the population would occur in th e 
Lumen Bioscience, Inc.  Confidential  Page 53 study. An event with a 10% rate in the population is 89% likely to occur among the 21 LMN -101 subjects 
in the study.   
While the sample size was not selected to provide a specific amount of statistical power to detect a 
statistically significant differen ce between the two treatment groups, assuming 18 subjects per 
treatment group complete the study, there is 80% power to detect a large risk reduction in attack rates 
(e.g., from 80% in the placebo group to 40.6% in the LMN -101 group) at the one -sided signi ficance level 
of 0.05.   
12.3 Population  
The Safety Analysis Set will be based on all subjects who received study treatment (LMN -101 or 
Placebo).  Subjects will be analyzed according to the treatment they received, even if this differs from 
the treatment they wer e randomized to (an as -treated approach).  
The Efficacy Analysis Set will be based on all subjects who received study treatment and complete the 
Campylobacter jejuni  challenge without significant protocol deviations (a per protocol approach). 
Subjects will be analyzed according to the treatment they received, even if this differs from the 
treatment they were randomized to.  
12.4 Statistical Analys es 
12.4.1  General Considerations  
Continuous variables will be summarized by treatment group with mean, SD, median, minimum , and 
maximum (or geometric mean and geometric CV% for log -transformed variables).  Frequency 
distributions of categorical variables will be presented by treatment group.  
Inferential statistics will not be used in the analysis of safety variables but  will be applied to the 
secondary and exploratory efficacy endpoints using 1-sided tests of significance at the 0. 05 level of 
significance and/or two-sided 90% confidence intervals.  It is expected that the study will be enrolled as 
two separate cohorts, an d cohort will be used as a stratification factor in statistical tests when 
applicable.  
The study analysis will be conducted using SAS, v9.4 or higher.  
12.4.2  Safety Analysis  
The analysis of safety and tolerability will  be completed on the safety analysis set . Saf ety will be 
evaluated from reported AEs, changes in clinical laboratory values , changes in vital signs and changes in 
ECG parameters . 
Safety data, including AEs, vital signs, ECG, and laboratory tests, will be listed by study subject.  
The incidence of all  reported AEs and treatment -related AEs will be tabulated by treatment group. 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and 
severity graded according to Common Terminology Criteria for Adverse Events (CTCA E), version 5.0.   An 
AE will be considered  treatment emergent if it occurs or worsens after the first dose of randomized 
study treatment.  
Frequencies and percentages of subjects with treatment emergent AEs and SAEs will  be summarized by  
MedDRA preferred t erm, system  organ system class, severity, and relationship to study drug. In the 
Lumen Bioscience, Inc.  Confidential  Page 54 event of multiple occurrences of the same AE with the same preferred term in the same subject, the AE 
will be reported as the number of AEs with the AE counted only once.   Treatment emergent AEs leading 
to death and causing premature discontinuation of study drug will also be summarized.  
Campylobacter  jejuni  challenge -related solicited adverse events , including diarrhea, fever, nausea, 
vomiting, abdominal pain, abdominal crampi ng, tenesmus, mucoid or bloody stools, constipation, 
headache, lightheadedness, fatigue, lack of appetite, muscle aches, chills, and joint pains , will be 
monitored from the time of challenge through Day 24. These will also be summarized by treatment 
group.  
Monitoring for Adverse Events of Special Interest (AESI) after Campylobacter  jejuni challenge will include 
clinically apparent signs or symptoms of Guillain -Barre syndrome (GBS), neurodegenerative changes, 
arthritis, uveitis, and myocarditis/pericarditis at each of the non in unit  visits, and during the final phone 
call. 
Clinical laborato ry results and changes from baseline in clinical laboratory results will be summarized by 
treatment group.  Shift tables will be constructed to tabulate categorical shifts in laboratory values from 
baseline to the minimum and maximum post -baseline values by  treatment group.  Categories will be 
based on the laboratory normal ranges and CTCAE Grade 3 toxicity thresholds.  
Vital signs and ECG parameters, and changes from baseline in vital signs and ECG parameters, will be 
summarized by treatment group.   Additiona lly, QTc measures (Fridericia’s formula) will be summarized 
in the following categories:  
1. QTc >450 to ≤480 msec  
2. QTc >480 to ≤500 msec  
3. QTc >500 msec  
4. QTc increase of >30 and ≤ 60 msec from baseline  
5. QTc increase of >60 msec from baseline  
 
Serum will be collected at baseline  and Day 24 for presence of anti -VHH antibodies. Anti -VHH antibody 
determinations will be performed  and summarized  if systemic absorption of VHH is demonstrated.  
Tolerability will be assessed by the proportion of participants completin g study drug and remaining on 
study (other than subjects dropping off for reasons other than study drug) and free from possibly drug -
related and dose -limiting SAEs to the end of Day 59. 
12.4.3  Analysis of Efficacy  
The planned statistical evaluation of efficacy wi ll compare the prospectively defined clinical and 
microbiological endpoints of campylobacteriosis rate and severity, diarrhea output (weight), severity, 
dysentery  (presence/absence) , and fever between treatment groups.  
Campylobacteriosis will be summarize d using frequencies and percentages by treatment group as well 
as 90% confidence intervals around the percentages.  The percentage of subjects with 
campylobacteriosis will be calculated for each treatment group  using the standard definition of: (# with 
endpoint / # receiving inoculum) x 100%.  The campylobacteriosis risk ratio (LMN -101 / placebo) will be 
presented.  The risk ratio  will be tested using the method of Cochrane -Mantel -Haenszel stratified by 
Lumen Bioscience, Inc.  Confidential  Page 55 enrollmen t cohort to determine if the risk ratio is statistically significantly different from 1 ; similar 
methodology will be used to construct a 90% asymptotic confidence interval around the risk ratio .   
Summary tables will also be created to detail quantitative and temporal features of the illness such as 
diarrhea stool frequency and volume, maximum temperature observed, and time to illness.  
The median duration of any campylobacteriosis clinical symptoms, diarrhea , and dysentery will be 
estimated with Kaplan -Meier survival analysis methodology and compared between treatment groups 
using the log -rank test.  
The geometric mean total weight of loose stools will be calculated for each treatment group and 
compared using an analysis of variance model with terms for tre atment group and enrollment cohort.  
Subjects with zero loose stool output will be imputed as the logarithm of half the smallest quantifiable 
output.  
The median, 25th percentile and 75th percentile of the maximum stool grad e for each subject and the 
Campylo bacter  jejuni  severity scale will each be calculated and  compared between treatment groups 
using the Cochran -Mantel -Haenszel row mean score test stratified by enrollment cohort.  
Rates of recurrence of Campylobacter  jejuni  stool shedding and campylobacter iosis clinical symptoms 
will be calculated and compared between treatment groups using the Cochrane -Mantel -Haenszel test 
stratified by enrollment cohort.  
Stool and blood biomarkers may also be summarized in a tabular format and graphed to demonstrate 
kinetic s of response. Qualitative (responder rates) and quantitative assessments (log -transformed 
values) will be analyzed. All statistical tests will be interpreted in a two -tailed fashion using p < 0. 10 to 
represent a significant difference.  
12.4.4  Planned Interim Ana lysis 
The initial cohort will be comprised of 21 subjects . After the initial cohort has completed the in -center 
portion of the study, an unblinded statistician will perform an interim analysis to allow a data safety 
monitoring board to determine if the tri al should continue based on safety . 
13. Data handling and recordkeeping  
The primary source document for this study will be the subject's phase one unit’s  chart. The Principal 
Investigator will maintain complete and accurate documentation for the study, including any medical 
records  provided by potential participants , records detailing the progress of the study for each subject, 
laboratory reports, eCRFs, signed infor med consent forms for each study subject, drug disposition 
records, correspondence with the phase one unit’s IRB, the study monitor and the Sponsor, adverse 
event reports, and information regarding subject discontinuation and completion of the study. All 
required study data will be clearly and accurately recorded by authorized study personnel in the eCRFs. 
Only designated study site personnel shall record or change data in an eCRF. The Principal Investigator 
will be responsible for the procurement of data a nd for quality of data recorded in the eCRFs. Original 
observations entered directly into the eCRFs are considered  source data. Study -specific procedures 
detail how each form will be completed. The study coordinator will ensure accuracy of the case report 
forms. All source documents will be retained at the site.  
Lumen Bioscience, Inc.  Confidential  Page 56 For this study, the phase one unit will utilize the Medidata Rave data system for the collection of the 
study data in an electronic format. The data system , as implemented by the phase one unit,  will be 
designed based on the protocol requirements, the approved eCRF layouts and specifications, and in 
accordance with 21 CRF Part 11. The eCRF layouts and specifications define and identify the applicable 
source data that will be collected and captured in to the electronic data system. The applicable source 
data will be electronically transcribed by the site designee onto the eCRF (data entry screens) in the 
database system. The Principal Investigator is ultimately responsible for the accuracy of the data 
transcribed on the eCRF. Data monitoring and management will be performed in the electronic data 
system by the clinical research associate and the designated data management group.  
A detailed data management plan will be written and approved by the study te am and the PI. The plan 
will be drafted prior to study initiation but will be finalized before study close -out and database lock.  
14. Clinical trial material accountability  
The Principal Investigator is responsible for maintaining accurate records of the proce ssing and use of 
all clinical trial materials, including the receipt, disposition,  and return  and/or  disposal  of these 
supplies. All used, unused, or undispensed study medication must be accounted for by the Principal 
Investigator.  
Accurate records of chal lenge strain C. jejuni  preparation will be kept.  When the challenge strain is 
prepared for the study, the batch/lot number, date used, strain characteristics , and viability profile 
will be recorded. Colony forming units per mL of suspension will be determi ned for the challenge 
strain before and after administration to eligible study subjects.  
Drug accountability will be conducted during monitoring visits to ensure appropriate receipt, storage, 
dispensing, and documentation of returned Clinical Trial Materials.  
15. Quality control (QC)/quality assurance (QA)  
15.1 QC/QA monitoring  
During the study and at the close -out of the study, a monitor from Lumen Bioscience or its 
representative will have regular contacts with the investigational site, for the following:  
• Provide information and support to the Investigator(s)  
• Confirm that faci lities remain acceptable  
• Confirm that the investigational team is adhering to the protocol, data is being accurately 
recorded in the CRFs, and investigational product accountability checks are being performed  
• Perform source data verification. This includes  a comparison of the data in the CRFs with the 
subject’s medical records at the hospital or practice, and other records relevant to the study. 
This will require direct access to all original records for each subject (e.g., clinic charts)  
• Record and report any protocol deviations not previously sent to Lumen Bioscience  
• Confirm AEs and SAEs have been properly documented on CRFs and confirm any SAEs have been 
forwarded to Lumen Bioscience or its representative and those SAEs that met criteria for 
reporting hav e been forwarded to the IRBs and/or FDA  
Lumen Bioscience, Inc.  Confidential  Page 57 The monitor will be available between visits if the Investigator(s) or other staff needs information or 
advice. The PI assumes ultimate responsibility for the conduct of the study and remains readily 
accessible throu ghout the duration of the study.  
15.2 Audits and inspections  
Authorized representatives of Lumen Bioscience, a regulatory authority, or FDA may visit the site to 
perform audits or inspections, including source data verification. The purpose of a Lumen Bioscien ce 
audit or inspection is to systematically and independently examine all study -related activities and 
documents to determine whether these activities were conducted, and data were recorded, analyzed, 
and accurately reported according to the protocol, Good  Clinical Practice (GCP) guidelines of the 
International Conference on Harmonization, and any applicable regulatory requirements. The 
Investigator should contact Lumen Bioscience immediately if contacted by a regulatory agency about an 
inspection.  
The Inv estigator agrees to allow the monitor to inspect the drug storage area, study drug stocks, drug 
accountability records, subject charts and study source documents, and other records relative to study 
conduct.  
To ensure compliance with GCP and all applicabl e regulatory requirements, Lumen Bioscience may 
conduct one or more quality assurance audits.  
15.3 Protocol deviation management  
Other than minimal -risk changes, all unanticipated major problems involving human subjects or others 
will be reported promptly to t he IRBs, and no such changes will be made to the research without IRB 
approval unless necessary to eliminate apparent immediate hazards to human subjects. Minor minimal -
risk deviations necessitated during  the trial will be made on site as needed and docume nted for 
subsequent review within a reasonable time period.  
Deviations from the protocol that potentially impact on subject safety will be promptly reported to the 
Medical Monitor, IRBs, and the Sponsor. Other deviations will be reported at the time of con tinuing 
review.  
15.4 Clinical research monitoring  
Lumen Bioscience monitoring responsibilities will be provided by an independent Clinical Research 
Associate (CRA). Monitoring will be conducted according to an approved monitoring plan, and according 
to applicab le SOPs. The CRA or other authorized representatives of the Sponsor may inspect all 
documents and records maintained by the Principal Investigator, including, but not limited to, medical 
records (office, clinic, or hospital) and pharmacy records for the su bject in this study. The clinical study 
site will permit access to such records. The Principal Investigator will obtain, as part of informed 
consent, permission for authorized representatives of the Sponsor, or regulatory authorities, to review, 
in confide nce, any records identifying individuals in this clinical study.  
The Principal Investigator will notify the Sponsor within 24 hours following contact by a regulatory 
agency. The Principal Investigator and study coordinator will be available to respond to r easonable 
requests and audit queries made by authorized representatives of regulatory agencies. The Principal 
Investigator will provide the Sponsor with copies of all correspondence that may affect the review of the 
Lumen Bioscience, Inc.  Confidential  Page 58 current study or his/her qualification a s a Principal Investigator in clinical studies conducted by the 
Sponsor. The Sponsor will provide any needed assistance in responding to regulatory audits or 
correspondence. The Principal Investigator will permit independent auditors (employees of the Spon sor 
or an external company designated by the Sponsor) to verify source data validation of the regularly 
monitored clinical trial. The auditors will compare the entries in the CRFs with the source data and 
evaluate the study site for its adherence to the cl inical study protocol and GCP guidelines and applicable 
regulatory requirements. The Sponsor will arrange local monitoring prior to beginning, at initiation, 
during the study, and at closeout by the study monitor or designee.  
15.5 Medical Monitor (Sponsor)/Inde pendent Medical Monitor  
The Medical Monitor shall be available for consultation with the Principal Investigator and serves as 
liaison between the clinical study site and the Sponsor. The study investigators will consult with the 
Medical Monitor on issues r elated to subject enrollment and continued participation as needed. The 
Medical Monitor is required to review all unanticipated problems involving risk to subjects, SAEs, and all 
subject deaths associated with the protocol, and provide an unbiased written report of the event. At a 
minimum, the Medical Monitor should comment on the event outcomes, and in the case of a SAE or 
death, comment on the relationship to participation in the study. The Medical Monitor should indicate 
concurrence or non -concurrence wi th the details of the report provided by the Principal Investigator. 
Reports for events determined by either the Principal Investigator or Medical Monitor to be related or 
unrelated to participation and reports of events resulting in death should be prompt ly forwarded to the 
IRBs.  
In addition to the Sponsor’s Medical Monitor, an Independent Medical Monitor will function as an 
independent safety advocate for subjects per Army Regulation 70 -25 and DoD Instruction 3216.02. An 
Independent Medical Monitor is required to review all unanti cipated problems involving risk to subjects 
or others, SAEs, and all subject deaths associated with the protocol and provide an unbiased written 
report of the event. At a minimum, the Independent Medical Monitor should comment on the outcomes 
of the event or problem and, in the case of an SAE or death, comment on the relationship to 
participation in the study. The Independent Medical Monitor should also indicate whether he or she 
concurs with the details of the report provided by the Principal Investigator.  Reports for significant 
events determined by either the Principal Investigator or Independent Medical Monitor to be possibly or 
definitely related to participation and reports of events resulting in death should be promptly forwarded 
to the IRB.  
16. Regulator y, ethical and study oversight considerations  
16.1 Institutional Review Board  
The PI must verify that the IRB has approved the clinical protocol, Informed Consent Form, and 
recruitment materials for the investigation prior to conducting study evaluations. Initi al IRB approval, and 
all materials approved by the IRB for this study including the Informed Consent Form and recruitment 
materials , must be maintained by the Investigator and made available for inspection.  
Lumen Bioscience, Inc.  Confidential  Page 59 All amendments to the protocol, consent form , and/or questionnaires, including a change of PI, will be 
submitted to the IntegReview IRB  for review and approval prior to implementation. The PI is responsible 
for informing the IRB of any amendment to the protocol.  
The PI is also responsible for providing t he IRB with reports of any reportable serious adverse drug 
reactions from any other study conducted with the investigational product. Lumen Bioscience will provide 
this information to the PI.  
Progress reports and notifications of serious adverse drug react ions will be provided to th e IRB  according 
to FDA regulations and guidelines .  
16.2 Written informed consent  
The PI or research staff designee will ensure that the subject or legally authorized representative is given 
full and adequate oral and written information about the nature, purpose, possible risks, and potential 
benefits of the study. The subject or legally authorized representative must also be notified that the 
subject is free to discontinue from the study at any time. The subject or legally au thorized representative 
should be given the opportunity to ask questions and allowed time to consider the information provided.  
The subject’s signed and dated informed consent, or the signed and dated informed consent of a legally 
authorized representative , must be obtained before conducting any study procedures. The PI must 
maintain the original, signed Informed Consent Form. A copy of the signed Informed Consent Form must 
be given to the subject or legally authorized representative.  
16.3 Subject risk-mitigatio n strategies  
Subjects will be questioned and examined daily for evidence of infection and diarrhea complications. 
Vital signs will be recorded at least three times per day. Based on prior studies, infected subjects tend to 
develop illness with incubation p eriods of approximately 1 -3 days. Therapeutic benefit seems to be 
optimal if treatment is given within the first three days of symptom onset.  
The risk of diarrhea complications will be minimized by a conservative approach to timing of antibiotic 
administra tion — well within an interval that has been shown to be efficacious — and daily clinical 
monitoring. Stool output will be closely monitored.  All subjects will be treated no later than Day 6 post -
dosing. The subjects will be monitored for evidence of relap sed Campylobacter  jejuni  infection by  clinical  
symptoms  and repeat stool cultures  on Days  14, 21, 28, 35, 56, and 84. 
Aggressive fluid management will be undertaken to ensure the most common complication, 
dehydration, does not occur. The procedures to institute early oral and/or intravenous rehydration 
therapy are detailed in section 5.1 1. In addition to rehydration therapy, prospectively defined criteria 
and procedures to institute early antibiotic therapy are also fully described above.  To ensure clinical 
resolution and limit the  potential  for secondary  spread upon  discharge, predefined discharge criteria  
have  been established. Subjects will be  discharged from the clinical research center  phase of the study 
when they have had two days of antibiotics, clinical  symptoms  are resolved  or resolving , and  two 
consecutive  stool cultures ≥ 12 hours apart are negative for C. jejuni . 
Lumen Bioscience, Inc.  Confidential  Page 60 Systemic or severe gastrointestina l complications rarely occur with Campylobacter  jejuni  infection. The 
following clinical findings necessitate immediate consideration and management of complicated 
enteritis:  
• Physical examination compatible with an acute abdomen  
• Severe GI bleeding (any evidence of GI blood loss other than hemoccult positivity  only, with 
evidence of hemodynamic instability, decrease in hemoglobin, hypovolemia)   
• Sepsis (high fever: temperature >102 °F (39 °C), rigors, hemodynamic instability)  
Any of these findings require pr ompt clinical management and discussion with the Sponsor’s Medical 
Monitor and the Independent Medical Monitor.  The Pharmaron inpatient clinical facility is located 3 
blocks from the University of Maryland Medical Center. Arrangements are in place for tran sportation 
and admission of sick subjects from the inpatient clinical facility to the University of Maryland Medical 
Center.  
 
The C. jejuni strain has the potential for risk to both  the environment and  to the  research personnel. 
Campylobacter spp. are comm on commensals of many birds and mammals with  the usual route of 
transmission  to humans through consumption of contaminated meat, poultry, milk, and occasionally 
large waterborne outbreaks. Therefore, the risk to the environment regarding potential transmission  
outside  of the clinical  research facility  is low.  There is  a minimal  risk of acquiring C. jejuni infection  
associated  with  subject  inoculum  administration,  care activities on the ward, or processing C. jejuni -
infected stool. The risk to the en vironment will be reduced by ensuring that all human waste  products  
from  in center participant s are disinfected  with  bleach prior to disposal, ensuring all subjects comply  
with  discharge  criteria  (two  consecutive  negative stool cultures  ≥ 12 hours apart  for C. jejuni ), 
emphasizing importance of hand washing  for subjects  and staff, ensuring  proper disposal/cleaning  of 
linen,  and cohorting  subjects  in the clinical research facility  while shedding C. jejuni.  Additionally, 
subjects will not be discharged until they are no longer shedding the challenge strain as per procedures 
outlined in the protocol.  
If a recrudescent infection is detected, the follow -up clock  will be reset  for the individual who 
recrudesced.  The risk of recrudescent  infection  will be minimized  by the participation of only  
immunocompetent  individuals, the  use of an extended  duration of concurrent antibiotics  (five  days),  
monitoring  of clinical  symptoms,  and frequent  evaluation  of stool cultures. Follow -up stool cultures 
after discharge will be performed to demonstrate continued eradication of infection.  
If a subject is found to have recrudescence of infection, the following steps will be taken:  
• Testing will be performed to rule out C. difficile -associated diarrhea. The strain will be confirmed 
by clinical microbiology and PCR  testing  to confirm  that it is the study strain. Antibiotic 
sensitivity will be confirmed by the Clinical Microbiology Laboratory.  
• The subject  will be provided  a second  course  of azithromycin  500 mg  PO daily  for 10 days and 
ciprofloxacin 500 mg PO BID for 10 days (assuming the strain remains susceptible) and treated 
symptom . 
If a subject  cannot tol erate the planned antibiotic treatment , or if resistance emerges to both  
antibiotics, an alternative antibiotic  treatment will be Augmentin (875 mg PO BID for 10 days) or the oral 
third -generation cephalosporin, cefpodoxime (400 mg PO  BID for 10 days).  Decisions regarding 
Lumen Bioscience, Inc.  Confidential  Page 61 antibiotic use and  combination  of these  second -line agents  will be made  by the Principal Investigator on 
a case -by-case basis in consultation with the Medical Monitor.  
The subject  will have  stool  cultures  performed after the  completion  of antibiotic  therapy,  and then at 
recrudescence Days 14, 21, 28, 35, 56, and 84 (Day 0 = day of production of the stool demonstrating the 
recrudescence) to confirm clearance.  
The subject will have a telephone call approximat ely 180 days following the start  of the recrudescent 
episode to assess for any new chronic or serious adverse health events.  
16.4 Benefits  
There is no benefit that can be guaranteed to subjects for participating in this research study. However, 
there is potenti al societal benefit of the development of a Campylobacter preventative treatment . 
16.5 Subject compensation  
Compensation for participation will be provided only for completed study procedures designated for 
compensatory payment.  If a subject is eligible to part icipate in the investigational protocol after 
screening, the subject will be compensated for participation time and travel . Subjects will not be paid for 
missed follow -up visits and may forfeit some or all of  their bonus as a result of missed visits or non -
compliance.  
16.6 Provisions to protect  privacy of subjects and confidentiality of data 
The Principal Investigator will exercise all reasonable precautions within the constraints of the applicable 
regulatory requi rements to maintain the confidentiality of subjects’ identities. On exported electronic 
source data or any other documents submitted to the Sponsor, subjects will only be identified by subject 
number. Documents not for submission to the Sponsor, e.g., subj ect identification log and original ICF, 
will be maintained by the Principal Investigator in strict confidence.  
16.7 Safeguards for vulnerable subjects  
This study will not include individuals less than 18, incarcerated, or unable to  meet the requirements to 
sign the informed consent form.    
Lumen Bioscience, Inc.  Confidential  Page 62 17. References  
Abed E, Ihab N, Suliman E, Mahmoud A. Impact of spirulina on nutritional status, haematological profile and 
anaemia status in malnourished children in the Gaza strip: randomized clinical trial. Matern Pediatr Nutr . 
2016;2(2):1000110. doi: 10.4172/mpn.1000110  
Ajene, A. N., Fischer Walker, C. L., & Black, R. E. (2013). Enteric pathogens and reactive arthritis: a systematic 
review of Campylobacter, salmonella and Shigella -associated reactive arthritis.  Journal of heal th, 
population, and nutrition , 31(3), 299 –307. https://doi.org/10.3329/jhpn.v31i3.16515   
Azabji -Kenfack M, Dikosso SE, Loni EG, Onana EA, Sobngwi E, Gbaguidi E , et al.  Potential of Spirulina platensis  as a 
nutritional supplement in malnourished HIV -infected adults in sub -Saharan Africa: a randomised, single -
blind study. Nutr Metab Insights. 2011;4:29 -37. doi: 10.4137/NMI.S5862  
Baker MG, Kvalsvig A, Zhang J, Lake R, Sears A, Wilson N. Declining  Guillain -Barre syndrome after 
campylobacteriosis control, New Zealand, 1988 -2010. Emerg Infect Dis. 2012;18(2):226 -233. doi: 
10.3201/eid1802.111126  
Baqar, S., et al. (2010). "Recrudescent Campylobacter jejuni  Infection in an Immunocompetent Adult followin g 
Experimental Infection with a Well -Characterized Organism." Clinical and Vaccine Immunology 17(1): 80 -
86. 
Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental Campylobacter jejuni  infection in humans. 
J Infect Dis. 1988;157(3):472 -479. do i: 10.1093/infdis/157.3.472  
CDC. Antibiotic resistance threats in the United States. US Department of Health and Human Services, Centers for 
Disease Control and Prevention. 2013.  
CDC. Campylobacter (Campylobacteriosis) - Information for health professionals. Centers for Disease Cont rol and 
Prevention , National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) , Division of 
Foodborne, Waterborne, and Environmental Diseases (DFWED); 2017 [updated October 2, 2017]]. 
Available from: https://www.cdc.gov/campylobacter/technical.html  
Chamorro GA, Herrera G, Salazar M, Salazar S, Ulloa V. Subchronic toxicity study in rats fed Spirulina. J Pharm Belg. 
1988;43(1):29 -36. doi: no DOI available; PMID: 3132549  
Crowe JS, R oberts KJ, Carlton TM, Maggiore L, Cubitt MF, Ray KP , et al.  Oral delivery of the anti -tumor necrosis 
factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic 
exposure in cynomolgus monkeys. Drug Development  and Industrial Pharmacy. 2018;45(3):387 -394. doi: 
10.1080/03639045.2018.1542708  
di Guan C, Li P, Riggs PD, Inouye H. Vectors that facilitate the expression and purification of foreign peptides in 
Escherichia coli  by fusion to maltose -binding protein. Gene. 1988;67(1):21 -30. doi: 10.1016/0378 -
1119(88)90004 -2 
EFSA -ECDC. The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food in 2017. EFSA Journal . 2019;17(2):5598. doi: 10.2903/j.efsa.2019.5598  
FDA. Guidance for industry - Estimating the maximum safe starting dose in initial clinical trials for therapeutics in 
adult healthy volunteers. US Department of Health and Human Services, Food and Drug Admin istration, 
Center for Drug Evaluation and Research (CDER). 2005.  
FDA. CAP 2C0293: Final toxicology Review memorandum: safety review of Arthrospira (A.) platensis  
cyanobacterium (Spirulina, Spirulina Blue). US Department of Health and Human Services, Food and Drug 
Administration. 2012.  
Fox RD. Spirulina: production & potential. Aix -en-Provence: Edisud; 1996.  
Freedman DJ, Tacket CO, Delehanty A, Maneval DR, Nataro J, Crabb JH. Milk immunoglobulin with specific activity 
against purified colonization factor a ntigens can protect against oral challenge with enterotoxigenic 
Escherichia coli . J Infect Dis. 1998;177(3):662 -667. doi: 10.1086/514227  
Garaicoechea L, Olichon A, Marcoppido G, Wigdorovitz A, Mozgovoj M, Saif L , et al.  Llama -derived single -chain 
antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity  in vitro  and confer 
protection against diarrhea in mice. J Virol. 2008;82(19):9753 -9764. doi: 10.1128/JVI.00436 -08 
Lumen Bioscience, Inc.  Confidential  Page 63 Giallourou N, Medlock GL, Bolick DT, Medeiros PH, Ledwaba SE,  Kolling GL , et al.  A novel mouse model of 
Campylobacter jejuni  enteropathy and diarrhea. PLoS Pathog. 2018;14(3):e1007083. doi: 
10.1371/journal.ppat.1007083  
Godschalk PCR, Heikema AP, Gilbert M, Komagamine T, Ang CW, Glerum J , et al.  The crucial role of Campylobacter 
jejuni  genes in anti -ganglioside antibody induction in Guillain -Barré syndrome. The Journal of Clinical 
Investigation. 2004;114(11):1659 -1665. doi: 10.1172/JCI15707  
Gomez -Sebastian S, Nunez MC, Garaicoechea L, Alvarado C, Mozgovoj M, Lasa R , et al.  Rotavirus A -specific single -
domain antibodies produced in baculovirus -infected insect larvae are protective in vivo . BMC Biotechnol. 
2012;12:59. doi: 10.1186/1472 -6750 -12-59 
Guerry P. Campylobacter flagella: not just for motility. Trends Microbiol. 2007;15(10):456 -461. doi: 
10.1016/j.tim.2007.09.006  
Günaydin G, Yu S, Graslund T, Hammarstrom L, Marcotte H. Fusion of the mouse IgG1 Fc domain to the VHH 
fragment (ARP1) enhances protection in a mouse model of rotavirus. Sci Rep. 2016;6:30171. doi: 
10.103 8/srep30171  
Harmsen MM, van Solt CB, van Zijderveld -van Bemmel AM, Niewold TA, van Zijderveld FG. Selection and 
optimization of proteolytically stable llama single -domain antibody fragments for oral immunotherapy. 
Appl Microbiol Biotechnol. 2006;72(3):544 -551. doi: 10.1007/s00253 -005-0300 -7 
Heikema AP, Jacobs BC, Horst -Kreft D, Huizinga R, Kuijf ML, Endtz HP , et al.  Siglec -7 specifically recognizes 
Campylobacter jejuni  strains associated with oculomotor weakness in Guillain -Barre syndrome and Miller 
Fisher syndrome. Clin Microbiol Infect. 2013;19(2):E106 -112. doi: 10.1111/1469 -0691.12073  
Hernández -Lepe MA, López -Diaz JA, Rosa LA, Hernández -Torres RP, Wall -Medrano A, Juarez -Oropeza MA , et al.  
Double -blind randomised controlled trial of the independent and syn ergistic effect of Spirulina maxima  
with exercise (ISESE) on general fitness, lipid profile and redox status in overweight and obese subjects: 
study protocol. BMJ Open. 2017;7(6):e013744. doi: 10.1136/bmjopen -2016 -013744  
Hernández -Lepe MA, López -Diaz JA, J uárez -Oropeza MA, Hernández -Torres RP, Wall -Medrano A, Ramos -Jiménez 
A. Effect of Arthrospira (Spirulina ) maxima  supplementation and a systematic physical exercise program on 
the body composition and cardiorespiratory fitness of overweight or obese subject s: a double -blind, 
randomized, and crossover controlled trial. Mar Drugs. 2018;16(10):364. doi:  10.3390/md16100364  
Hussack G, Riazi A, Ryan S, van Faassen H, MacKenzie R, Tanha J , et al.  Protease -resistant single -domain antibodies 
inhibit Campylobacter jejuni motility. Protein Eng Des Sel. 2014;27(6):191 -198. doi: 
10.1093/protein/gzu011  
Jester  B, Zhao H, Gewe M, Adame  T, Perruzza L, Bolick D,  et al.  Expression and manufacturing of orally delivered 
protein therapeutics in spirulina . Nature Biotech nology. 2021. In press.  
Kaakoush NO, Castano -Rodriguez N, Mitchell HM, Man SM. Global epidemiology of Campylobacter infection. Clin 
Microbiol Rev. 2015;28(3):687 -720. doi: 10.1128/CMR.00006 -15 
Kalafati M, Jamurtas AZ, Nikolaidis MG, Paschalis V, Theodorou AA, Sakellariou GK , et al.  Ergogenic and antioxidant 
effects of spirulina supplementation in humans. Med Sci Sports Exerc. 2010;42(1):142 -151. doi: 
10.1249/MSS.0b013e3181ac 7a45  
Karkos PD, Leong SC, Karkos CD, Sivaji N, Assimakopoulos DA. Spirulina in clinical practice: evidence -based human 
applications. Evid Based Complement Alternat Med. 2011;2011:531053. doi: 10.1093/ecam/nen058  
Keithlin J, Sargeant J, Thomas MK, Fazil A. Systematic review and meta -analysis of the proportion of Campylobacter 
cases that develop chronic sequelae. BMC Public Health. 2014;14:1203. doi: 10.1186/1471 -2458 -14-1203  
Kirkpatrick BD, Lyon CE, Porter CK, Maue AC, Guerry P, Pierce KK , et al.  Lack of homologous protection against 
Campylobacter jejuni CG8421 in a human challenge model. Clin Infect Dis. 2013;57(8):1106 -1113. doi: 
10.1093/cid/cit454  
Kotloff KL, Platts -Mills JA, Nasrin D, Roose A, Blackwelder WC, Levine MM. Global burden of diarrh eal diseases 
among children in developing countries: incidence, etiology, and insights from new molecular diagnostic 
techniques. Vaccine. 2017;35(49 Pt A):6783 -6789. doi: 10.1016/j.vaccine.2017.07.036  
Lee EH, Park JE, Choi YJ, Huh KB, Kim WY. A randomized study to establish the effects of spirulina in type 2 diabetes 
mellitus patients. Nutr Res Pract. 2008;2(4):295 -300. doi: 10.4162/nrp.2008.2.4.295  
Lindow, J. C., et al. (2010). "Caught in the act: in vivo development of macrolide resistance to Campylobacte r jejuni  
infection." J Clin Microbiol 48(8): 3012 -3015.  
Lumen Bioscience, Inc.  Confidential  Page 64 Liu J, Platts -Mills JA, Juma J, Kabir F, Nkeze J, Okoi C , et al.  Use of quantitative molecular diagnostic methods to 
identify causes of diarrhoea in children: a reanalysis of the GEMS case -control study. Lancet. 
2016;388(10051):1291 -1301. doi: 10.1016/s0140 -6736(16)31529 -x 
Lu HK, Hsieh CC, Hsu JJ, Yang YK, Chou HN. Pre ventive effects of Spirulina platensis  on skeletal muscle damage 
under exercise -induced oxidative stress. Eur J Appl Physiol. 2006;98(2):220 -226. doi: 10.1007/s00421 -006-
0263 -0 
Luangtongkum T, Jeon B, Han J, Plummer P, Logue CM, Zhang Q. Antibiotic resista nce in Campylobacter: 
emergence, transmission and persistence. Future Microbiol. 2009;4(2):189 -200. doi: 
10.2217/17460913.4.2.189  
Maffey L, Vega CG, Mino S, Garaicoechea L, Parreno V. Anti -VP6 VHH: an experimental treatment for Rotavirus A -
associated disea se. PLoS One. 2016;11(9):e0162351. doi: 10.1371/journal.pone.0162351  
Mani UV, Desai S, Iyer U. Studies on the long -term effect of Spirulina supplementation on serum lipid  profile and 
glycated proteins in NIDDM patients. J Nutraceuticals Funct Med Foods. 20 00;2(3):25 -32. doi: 
10.1300/J133v02n03_03  
Marcel AK, Ekali LG, Eugene S, Arnold OE, Sandrine ED, von der Weid D , et al.  The effect of Spirulina platensis  
versus soybean on insulin resistance in HIV -infected patients: a randomized pilot study. Nutrients. 
2011;3(7):712 -724. doi: 10.3390/nu3070712  
Marles RJ, Barrett ML, Barnes J, Chavez ML, Gardiner P, Ko R , et al.  United States pharmacopeia safety evaluation 
of spirulina. Crit Rev Food Sci Nutr. 2011;51(7):593 -604. doi: 10.1080/10408391003721719  
Masuda K, Chi tundu M. Multiple micronutrient supplementation using Spirulina platensis  during the first 1000 days 
is positively associated with development in children under five years: a follow up of a randomized trial in 
Zambia. Nutrients. 2019;11(4):730. doi: 10.339 0/nu11040730  
Mazokopakis EE, Papadomanolaki MG, Fousteris AA, Kotsiris DA, Lampadakis IM, Ganotakis ES. The 
hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a 
Cretan population with non-alcoholic fatty liver disease: a prospective pilot study. Ann Gastroenterol. 
2014;27(4):387 -394. doi: no DOI available; PMCID: PMC4188938  
Miczke A, Szulinska M, Hansdorfer -Korzon R, Kregielska -Narozna M, Suliburska J, Walkowiak J , et al.  Effects of 
spirulina consumption on body weight, blood pressure, and endothelial function in overweight 
hypertensive Caucasians: a double -blind, placebo -controlled, randomized trial. Eur Rev Med Pharmacol Sci. 
2016;20(1):150 -156. doi: no DOI available; PMID: 26813468  
Morooka T, Umeda A, Amako K. Motility as an intestinal colonization factor for Campylobacter jejuni . J Gen 
Microbiol. 1985;131(8):1973 -1980. doi: 10.1099/00221287 -131-8-1973  
Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C , et al.  Disability -adjusted life years (DALYs) for 
291 diseases and injuries in 21 regions, 1990 –2010: a systematic analysis for the Global Burden of Disease 
Study 2010. Lancet. 2012;380(9859):2197 -2223. doi: 10.1016/s0140 -6736(12)61689 -4 
Niang K, Ndiaye P, Faye A, Tine JAD, Di ongue FB, Camara MD , et al.  Spirulina supplementation in pregnant women 
in the Dakar region (Senegal). Open Journal of Obstetrics and Gynecology. 2017;7(1):147 -154. doi: 
10.4236/ojog.2017.71016  
Nurbhai S, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Ray KP, et al.  Oral anti -tumour necrosis factor domain 
antibody V565 provides high intestinal concentrations, and reduces markers of inflammation in ulcerative 
colitis patients. Scientific Reports. 2019;9(1). doi: 10.1038/s41598 -019-50545 -x 
Otto W, Najnigier B , Stelmasiak T, Robins -Browne RM. Randomized control trials using a tablet formulation of 
hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in 
volunteers. Scand J Gastroenterol. 2011;46(7 -8):862 -868. doi: 10.3109/0 0365521.2011.574726  
Parikh P, Mani U, Iyer U. Role of spirulina in the control of glycemia and lipidemia in type 2 diabetes mellitus. J Med 
Food. 2001;4(4):193 -199. doi: 10.1089/10966200152744463  
Park HJ, Lee YJ, Ryu HK, Kim MH, Chung HW, Kim WY. A randomized double -blind, placebo -controlled  study to 
establish the effects of spirulina in elderly Koreans. Ann Nutr Metab. 2008;52(4):322 -328. doi: 
10.1159/000151486  
Platts -Mills JA, Kosek M. Update on the burden of Campylobacter in developing countries. Curr Opin Infect Dis. 
2014;27(5):444 -450. doi: 10.1097/QCO.0000000000000091  
Lumen Bioscience, Inc.  Confidential  Page 65 Platts -Mills JA, Babji S, Bodhidatta L, Gratz J, Haque R, Havt A , et al.  Pathogen -specific burdens of community 
diarrhoea in developing countries: a multisite birth cohort study (M AL-ED). Lancet Glob Health. 
2015;3(9):e564 -e575. doi: 10.1016/s2214 -109x(15)00151 -5 
Poly F, Read TD, Chen YH, Monteiro MA, Serichantalergs O, Pootong P , et al.  Characterization of two 
Campylobacter jejuni  strains for use in volunteer experimental -infection  studies. Infect Immun. 
2008;76(12):5655 -5667. doi: 10.1128/IAI.00780 -08 
Rees J, Soudain S, Gregson N, Hughes R. Campylobacter jejuni infection and Guillain -Barre syndrome. N Engl J Med. 
1995;333:1374 -1379.  
Riazi A, Strong PC, Coleman R, Chen W, Hirama T,  van Faassen H , et al.  Pentavalent single -domain antibodies 
reduce Campylobacter jejuni  motility and colonization in chickens. PLoS One. 2013;8(12):e83928. doi: 
10.1371/journal.pone.0083928  
Riddle, M.S., Gutierrez, R.L., Verdu, E.F.  et al.  The Chronic Gastrointestinal Consequences Associated With 
Campylobacter.  Curr Gastroenterol Rep  14, 395–405 (2012). https://doi.org/10.1007/s11894 -012-0278 -0  
Rimmer JE, Harro C, Sack DA, Talaat KR, Gutierrez RL, DeNearing B , et al.  Rifaximin fails to prevent 
campylobacteriosis in the human challenge model: a randomized, double -blind, placebo -controlled trial. 
Clin Infect Dis. 2018;66(9):1435 -1441. doi: 10.1093/cid/cix1014  
Romay C, Armesto J, Remirez D, Gonzalez R, Ledon N, Garcia I. Antioxidant and anti -inflammatory properties of C -
phycocyanin from blue -green algae. Inflamm Res. 1998;47(1):36 -41. doi: 10.1007/s000110050256  
Sarker SA, Jakel M, Sultana S, Alam NH, Bardhan PK, Chisti MJ , et al.  Anti-rota virus protein reduces stool output in 
infants with diarrhea: a randomized placebo -controlled trial. Gastroenterology. 2013;145(4):740 -748 e748. 
doi: 10.1053/j.gastro.2013.06.053  
Savarino SJ, McKenzie R, Tribble DR, Porter CK, O'Dowd A, Cantrell JA , et al.  Prophylactic efficacy of hyperimmune 
bovine colostral antiadhesin antibodies against enterotoxigenic Escherichia coli  diarrhea: a randomized, 
double -blind, placebo -controlled, phase 1 trial. J Infect Dis. 2017;216(1):7 -13. doi: 10.1093/infdis/jix144  
Sprost on EL, Wimalarathna HML, Sheppard SK. Trends in fluoroquinolone resistance in Campylobacter. Microb 
Genom. 2018;4(8). doi: 10.1099/mgen.0.000198  
Steele J, Sponseller J, Schmidt D, Cohen O, Tzipori S. Hyperimmune bovine colostrum for treatment of GI 
infecti ons: a review and update on Clostridium difficile . Hum Vaccin Immunother. 2013;9(7):1565 -1568. 
doi: 10.4161/hv.24078  
Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. Efficacy of bovine milk immunoglobulin 
concentrate in preventing illness a fter Shigella flexneri  challenge. Am J Trop Med Hyg. 1992;47(3):276 -283. 
doi: 10.4269/ajtmh.1992.47.276  
Tribble DR, Baqar S, Carmolli MP, Porter C, Pierce KK, Sadigh K , et al.  Campylobacter jejuni  strain CG8421: a refined 
model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects. 
Clin Infect Dis. 2009;49(10):1512 -1519. doi: 10.1086/644622  
Troeger C, Blacker BF, Khalil IA, Rao PC, Cao S, Zimsen SRM , et al.  Estimates of the global, regional, and national 
morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global 
Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1211 -1228. doi: 10.1016/s1473 -
3099(18)303 62-1 
van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, Bellamy K , et al.  Reduction in morbidity of rotavirus 
induced diarrhoea in mice by yeast produced monovalent llama -derived antibody fragments. Vaccine. 
2006;24(19):4130 -4137. doi: 10.1016/j.v accine.2006.02.045  
Virdi V, Coddens A, De Buck S, Millet S, Goddeeris BM, Cox E , et al.  Orally fed seeds producing designer IgAs 
protect weaned piglets against enterotoxigenic Escherichia coli  infection. Proc Natl Acad Sci U S A. 
2013;110(29):11809 -11814. doi: 10.1073/pnas.1301975110  
Virdi V, Palaci J, Laukens B, Ryckaert S, Cox E, Vanderbeke E , et al.  Yeast -secreted, dried and food -admixed 
monomeric IgA prevents gastrointestinal infection in a piglet model. Nat Biotechnol. 2019;37(5):527 -530. 
doi: 10.1038/ s41587 -019-0070 -x 
Walker IH, Hsieh PC, Riggs PD. Mutations in maltose -binding protein that alter affinity and solubility properties. 
Appl Microbiol Biotechnol. 2010;88(1):187 -197. doi: 10.1007/s00253 -010-2696 -y 
Lumen Bioscience, Inc.  Confidential  Page 66 Yamani E, Kaba -Mebri J, Mouala C, Gresenguet G, Rey JL. [Use of spirulina supplement for nutritional management 
of HIV -infected patients: study in Bangui, Central African Republic]. Med Trop (Mars). 2009;69(1):66 -70. 
doi: no DOI available; PMID: 19499738  
Zeinalian R, Farhangi MA, Shariat A, Saghafi -Asl M. The effects of Spirulina platensis on anthropometric indices, 
appetite, lipid profile and serum vascular endothelial growth factor (VEGF) in obese individuals: a 
randomized double blinded placebo controlled trial. BMC Complement Altern Med. 2017;17(1 ):225. doi: 
10.1186/s12906 -017-1670 -y 